var title_f31_11_31920="Brow ptosis";
var content_f31_11_31920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Brow ptosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lowering of the brow can occur as a natural feature of aging. Note the difference in brow position between the younger individual on the left and the middle-aged person on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31920=[""].join("\n");
var outline_f31_11_31920=null;
var title_f31_11_31921="Bullous Vibrio vulnificus";
var content_f31_11_31921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous lesions in Vibrio vulnificus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distinctive bullous skin lesions are seen in approximately 75 percent of patients with V. vulnificus infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn Morris Jr, MD, MPH, TM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31921=[""].join("\n");
var outline_f31_11_31921=null;
var title_f31_11_31922="Zinc oxide: Pediatric drug information";
var content_f31_11_31922=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zinc oxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"    see \"Zinc oxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/25/14740?source=see_link\">",
"    see \"Zinc oxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ammens&reg; Original Medicated [OTC];",
"     </li>",
"     <li>",
"      Ammens&reg; Shower Fresh [OTC];",
"     </li>",
"     <li>",
"      Balmex&reg; [OTC];",
"     </li>",
"     <li>",
"      Boudreaux's&reg; Butt Paste [OTC];",
"     </li>",
"     <li>",
"      Critic-Aid Skin Care&reg; [OTC];",
"     </li>",
"     <li>",
"      Desitin&reg; Creamy [OTC];",
"     </li>",
"     <li>",
"      Desitin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zincofax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply several times daily to affected area",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=see_link\">",
"      see \"Zinc oxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adults: Topical: Apply several times daily to affected area",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Balmex&reg;: 11.3% (60 g, 120 g, 480 g) [contains aloe, benzoic acid, soybean oil, and vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [stick]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Balmex&reg;: 11.3% (56 g) [contains aloe, benzoic acid, soybean oil, and vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 20% (30 g, 60 g, 454 g); 40% (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desitin&reg;: 40% (30 g, 60 g, 90 g, 120 g, 270 g, 480 g) [contains cod liver oil and lanolin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desitin&reg; Creamy: 10% (60 g, 120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Boudreaux's&reg; Butt Paste: 16% (30 g, 60 g, 120 g, 480 g) [contains castor oil, boric acid, mineral oil, and Peruvian balsam]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Critic-Aid Skin Care&reg;: 20% (71 g, 170 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ammens&reg; Original Medicated: 9.1% (312 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ammens&reg; Shower Fresh: 9.1% (312 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Ointment",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only; do not use in the eyes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid prolonged storage at temperatures &gt;30&deg;C",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protective coating for mild skin irritations and abrasions; soothing and protective ointment to promote healing of chapped skin, diaper rash",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local: Irritation, skin sensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zinc oxide or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13889735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zinc oxide is not expected to be absorbed systemically following topical administration to healthy skin (Newman, 2009). Systemic absorption would be required in order for zinc oxide to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild astringent, protective and weak antiseptic action",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/25/14740?source=see_link\">",
"      see \"Zinc oxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paste is easily removed with mineral oil",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adam R, \"Skin Care of the Diaper Area,\"",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 2008, 25(4):427-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/11/31922/abstract-text/18789081/pubmed\" id=\"18789081\" target=\"_blank\">",
"        18789081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visscher MO, \"Update on the Use of Topical Agents in Neonates,\"",
"      <i>",
"       Newborn &amp; Infant Nursing Reviews",
"      </i>",
"      , 2009, 9(1):33362-80.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12893 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31922=[""].join("\n");
var outline_f31_11_31922=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235778\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235779\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050655\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445306\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050652\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235771\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235761\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050658\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050653\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050657\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235790\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050660\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300238\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223736\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13889735\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050651\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050654\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/53/15187?source=related_link\">",
"      Zinc oxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/25/14740?source=related_link\">",
"      Zinc oxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31923="Mucosal barrier gel: Patient drug information";
var content_f31_11_31923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mucosal barrier gel: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11923?source=see_link\">",
"     see \"Mucosal barrier gel: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7290545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Episil&reg;;",
"     </li>",
"     <li>",
"      Gelclair&reg; [DSC];",
"     </li>",
"     <li>",
"      Mucotrol&trade;;",
"     </li>",
"     <li>",
"      MuGard&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15897940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mouth sores.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat canker sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15896979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4094662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mucosal coating agent or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Episil&reg;: If you are allergic to peanuts, soya, or peppermint oil.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15896981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15896982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699035",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15897958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Episil&reg;: Spray into mouth and let film form. Do not swallow. Wait 5 minutes before you eat of drink anything.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095025",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gelclair&reg;: Mix 1 tablespoonful (15 mL) or 1 packet to 40 mL of water and stir. Swish solution in the mouth for 1 minute and spit out. Do not drink or eat for at least 1 hour after using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mucotrol&trade;: Swish wafer in your mouth and let it melt slowly. Do not drink or eat for at least 1 hour after using.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       MuGard&trade;: Rinse 1 to 2 teaspoonfuls (5 to 10 mL) in mouth for 1 minute, then spit out or swallow. Do not drink or eat for at least 1 hour after using.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15896980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15897983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4095030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Episil&reg;: Use within 1 month after opening.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15896983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87668 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-8B92F8E3C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31923=[""].join("\n");
var outline_f31_11_31923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7290545\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897940\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896979\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896981\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896982\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897958\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896980\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897983\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896983\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11923?source=related_link\">",
"      Mucosal barrier gel: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31924="CPA radiograph and angiogram";
var content_f31_11_31924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Chronic pulmonary aspergillosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Chest radiograph showing a large left upper lobe cavity, with some pleural thickening and minor pericavitary infiltrates inferiorly, with no evidence of an aspergilloma. Otherwise the lung fields are abnormal, with subtle infiltrates most consistent with sarcoidosis. He presented with significant hemoptysis, weight loss, cough and fatigue over several months.",
"    <br>",
"     (B) Bronchial artery angiogram in the same patient, showing a extensive network of additional vessels surrounding the empty cavity, which were successfully embolized.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Denning, DW. Chronic aspergillosis. In: Aspergillus fumigatus and aspergillosis, Latge, JP, Steinbach, WJ (Eds). ASM Press, Washington, DC 2009. Copyright &copy; 2009 ASM Press.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31924=[""].join("\n");
var outline_f31_11_31924=null;
var title_f31_11_31925="Living unrelated donors in renal transplantation";
var content_f31_11_31925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Living unrelated donors in renal transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31925/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/11/31925/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widening gap between the demand and supply of donor kidneys has led to a call for an expansion in the potential donor pool. Efforts have been made to increase the number of available grafts retrieved by expanding the donor criteria. Such efforts include using donors at the extremes of age, double kidney transplants from marginal donors, extended criteria donors, and the use of living kidney donors (LKD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kidney donation by biologically unrelated persons has been attempted in different areas of the world, including the middle and far east [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These donations have received adverse publicity because of a combination of factors, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unresolved ethical issues including donor payment and possible coercion",
"     </li>",
"     <li>",
"      Unacceptably high donor and recipient morbidity and mortality",
"     </li>",
"     <li>",
"      Poor allograft survival rates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, such concerns have not materialized in patients accepting kidneys from unrelated donors in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. In addition, donor payment is a federal offense (National Organ Transplant Act, 1972). Living unrelated donors currently comprise more than 30 percent of all living donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues pertaining to living unrelated kidney donation, including donor evaluation and outcome, are reviewed here. A review of general issues pertaining to the kidney donor, whether related or unrelated to the recipient, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=see_link\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DONOR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ethical considerations surrounding living unrelated organ donation in the United States are somewhat similar to those involved in living related organ donation. Thus far, living unrelated kidney donation has been based upon altruistic ideals and has not been driven by economic incentives; however, some clinicians argue that the debate concerning the sale of kidneys should be reopened [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/16\">",
"     16",
"    </a>",
"    ]. Within the United States, CMS (Centers for Medicare and Medicaid Services) has regulated the participation of an \"independent living donor advocate (ILDA)\" into the evaluation of all living donors, whether related, unrelated or altruistic. One of the primary roles of the ILDA is to ensure the potential donor is free of coercion from the potential recipient or other involved individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The basic medical evaluation is the same as that for living related donors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=see_link\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=see_link\">",
"     \"C4d staining in renal allografts and treatment of antibody mediated rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The purpose of the evaluation is not to find the \"perfect\" donor, but to ensure that a potential donor is not jeopardized to an extent beyond the operative risk, and does not pose a risk of transmissible infection to the recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF DONOR NEPHRECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major concern about living donors is the long-term impact of having a solitary kidney with risk of developing hypertension, proteinuria and chronic kidney disease. Studies suggested that the risk of such complications appears to be quite small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/20\">",
"     20",
"    </a>",
"    ]. To better understand these risks, there continue to be calls for the establishment of long term living donor registries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\", section on 'Risk of donor nephrectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ALLOGRAFT OUTCOME AFTER KIDNEY DONATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcomes from a HLA-mismatched pairing are similar to those of haploidentical relatives. The one-year values are comparable to graft survival rates for recipients of living-related donor kidneys and better than that with deceased donor kidneys. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .) This survival benefit with living unrelated donor kidneys occurs despite a greater degree of HLA-mismatching and an increased rate of acute rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term graft survival of LURD kidneys is also encouraging. In the 2008 annual report of the scientific registry of transplant recipients, for example, the unadjusted five-year survival of LURD kidneys was the same as that of living related donor kidneys (approximately 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the number of HLA mismatches is similar for spousal donors and the three to four HLA mismatched cadaveric donors, the better results with living donors is best explained by less ischemic injury and the transplantation of \"healthier\" grafts. Other mechanisms that have been thought to contribute include improved patient compliance with immunosuppressive medications, less susceptibility to underlying kidney disorders (particularly focal segmental glomerulosclerosis and diabetes mellitus), and possible tolerance to spousal antigens by sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the last hypothesis seems unlikely since recipients of LURD kidneys experience a similar number of acute rejection episodes and require as much immunosuppressive therapy as recipients of living-related grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXPANSION OF LIVING UNRELATED DONOR POOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been multiple efforts to expand the number of living donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. One method is the establishment of kidney paired donation (KPD) programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In this system, living donors who are incompatible with their intended recipients either because of ABO incompatibility or because of sensitization (leading to a positive cross match) participate in a \"donor pool\", resulting in an expanded availability of organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of a national paired kidney exchange pilot program is underway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/29\">",
"     29",
"    </a>",
"    ]. The national Organ Procurement and Transplantation Network (OPTN), operated under federal contract by United Network for Organ Sharing (UNOS), is coordinating the project, although limited numbers of transplants have resulted thus far. Most recently, an independent, nonprofit organization entitled the National Kidney Registry (",
"    <a class=\"external\" href=\"file://www.kidneyregistry.org/\">",
"     www.kidneyregistry.org",
"    </a>",
"    ) has developed a very successful algorithm that has permitted increasing numbers of kidney paired donation transplants.",
"   </p>",
"   <p>",
"    Another strategy is to consider a nondirected live-kidney donor (sometimes referred to as altruistic donors or \"good samaritan\" donors). These individuals offer to donate a kidney, but do not identify the specific recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. A 2002 United States national conference report was published outlining some ethical and practical guidelines for centers considering the use of kidneys from a nondirected live-kidney donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/33\">",
"     33",
"    </a>",
"    ]. In the 2005 Scientific Registry of Transplant Recipients Report, there were 88 non-directed donations (among a total of 2343 living unrelated donors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/14\">",
"     14",
"    </a>",
"    ]. Perhaps the most exciting recent development is the realization that an altruistic donor can trigger an open ended chain of transplants.",
"   </p>",
"   <p>",
"    Some regions of the United Network for Organ Sharing region have also instituted a system where a person waiting for a deceased donor kidney is given a higher priority if a living relative donates a kidney to another recipient, resulting in the patient coming off the waiting list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This practice, however, may harm standard blood type O waiting list candidates if ABO-incompatible donor-recipient pairs are allowed to participate.",
"   </p>",
"   <p>",
"    An increase in living donation rates, whether living related or unrelated, may also occur if patient education is improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study, 122 patients were randomly assigned to clinic-based education alone or clinic-based plus home based education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31925/abstract/37\">",
"     37",
"    </a>",
"    ]. The combined program resulted in significantly more living kidney donor transplantations (52 versus 30 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/46/25315?source=see_link\">",
"       \"Patient information: Kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Efforts to increase the number of available kidney allografts include the use of living kidney donors. This includes kidney donation by biologically unrelated persons. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ethical considerations surrounding living unrelated organ donation in the United States are somewhat similar to those involved in living related organ donation. Thus far, living unrelated kidney donation has been based upon altruistic ideals and has not been driven by economic incentives. The basic medical evaluation is the same as that for living related donors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Donor evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major concern about living donors is the long-term impact of having a solitary kidney. This is discussed separately. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk of donor nephrectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=see_link\">",
"       \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The outcomes from a HLA-mismatched pairing are similar to those of haploidentical relatives. The one-year values are comparable to graft survival rates for recipients of living-related donor kidneys and better than that with deceased donor kidneys. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Allograft outcome after kidney donation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been multiple efforts to expand the living unrelated donor pool. One method is the establishment of a paired-kidney-exchange program. Another strategy is to consider a nondirected live-kidney donor (sometimes referred to as altruistic donors or \"good samaritan\" donors). These individuals offer to donate a kidney, but do not identify the specific recipient. An increase in living donation rates, whether living related or unrelated, may also occur if patient education is improved. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Expansion of living unrelated donor pool'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/1\">",
"      Jacobbi LM, McBride VA, Etheredge EE, et al. The risks, benefits, and costs of expanding donor criteria. A collaborative prospective three-year study. Transplantation 1995; 60:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/2\">",
"      Lee CM, Scandling JD, Shen GK, et al. The kidneys that nobody wanted: support for the utilization of expanded criteria donors. Transplantation 1996; 62:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/3\">",
"      Johnson LB, Kno PC, Dafoe DC, et al. Double adult renal allografts: a technique for expansion of the cadaveric kidney donor pool. Surgery 1996; 120:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/4\">",
"      O'Connor KJ, Delmonico FL. Increasing the supply of kidneys for transplantation. Semin Dial 2005; 18:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/5\">",
"      Chkhotua AB, Klein T, Shabtai E, et al. Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. Urology 2003; 62:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/6\">",
"      Ghods AJ, Savaj S. Iranian model of paid and regulated living-unrelated kidney donation. Clin J Am Soc Nephrol 2006; 1:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/7\">",
"      Participants in the International Summit on Transplant Tourism and Organ Trafficking Convened by the Transplantation Society and International Society of Nephrology in Istanbul, Turkey, April 30-May 2, 2008. The Declaration of Istanbul on organ trafficking and transplant tourism. Transplantation 2008; 86:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/8\">",
"      Salahudeen AK, Woods HF, Pingle A, et al. High mortality among recipients of bought living-unrelated donor kidneys. Lancet 1990; 336:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/9\">",
"      Cameron JS, Hoffenberg R. The ethics of organ transplantation reconsidered: paid organ donation and the use of executed prisoners as donors. Kidney Int 1999; 55:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/10\">",
"      Sever MS, Kazancio��lu R, Yildiz A, et al. Outcome of living unrelated (commercial) renal transplantation. Kidney Int 2001; 60:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/11\">",
"      Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol 2005; 16:2098.",
"     </a>",
"    </li>",
"    <li>",
"     The scientific registry of transplant recipients at file://www.ustransplant.org (Accessed February, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/13\">",
"      Gaston RS. Improving access to renal transplantation. Semin Dial 2005; 18:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/14\">",
"      Marks WH, Wagner D, Pearson TC, et al. Organ donation and utilization, 1995-2004: entering the collaborative era. Am J Transplant 2006; 6:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/15\">",
"      Andreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 2007; 7:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/16\">",
"      Radcliffe-Richards J, Daar AS, Guttmann RD, et al. The case for allowing kidney sales. International Forum for Transplant Ethics. Lancet 1998; 351:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/17\">",
"      Kasiske BL, Bia MJ. The evaluation and selection of living kidney donors. Am J Kidney Dis 1995; 26:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/18\">",
"      Bia MJ, Ramos EL, Danovitch GM, et al. Evaluation of living renal donors. The current practice of US transplant centers. Transplantation 1995; 60:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/19\">",
"      Rodrigue JR, Pavlakis M, Danovitch GM, et al. Evaluating living kidney donors: relationship types, psychosocial criteria, and consent processes at US transplant programs. Am J Transplant 2007; 7:2326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/20\">",
"      Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. Kidney Int 1995; 48:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/21\">",
"      Emara M, Ragheb A, Hassan A, Shoker A. Evidence for a need to mandate kidney transplant living donor registries. Clin Transplant 2008; 22:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/22\">",
"      Fuller TF, Feng S, Brennan TV, et al. Increased rejection in living unrelated versus living related kidney transplants does not affect short-term function and survival. Transplantation 2004; 78:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/23\">",
"      Futagawa Y, Waki K, Gjertson DW, Terasaki PI. Living-unrelated donors yield higher graft survival rates than parental donors. Transplantation 2005; 79:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/24\">",
"      Lowell JA, Brennan DC, Shenoy S, et al. Living-unrelated renal transplantation provides comparable results to living-related renal transplantation: a 12-year single-center experience. Surgery 1996; 119:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/25\">",
"      Israni AK, Halpern SD, Zink S, et al. Incentive models to increase living kidney donation: encouraging without coercing. Am J Transplant 2005; 5:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/26\">",
"      Spital A. Increasing the pool of transplantable kidneys through unrelated living donors and living donor paired exchanges. Semin Dial 2005; 18:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/27\">",
"      Ross LF, Rubin DT, Siegler M, et al. Ethics of a paired-kidney-exchange program. N Engl J Med 1997; 336:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/28\">",
"      Delmonico FL. Exchanging kidneys--advances in living-donor transplantation. N Engl J Med 2004; 350:1812.",
"     </a>",
"    </li>",
"    <li>",
"     file://optn.transplant.hrsa.gov/news/newsDetail.asp?id=1344.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/30\">",
"      Spital A. Should people who donate a kidney to a stranger be permitted to choose their recipients? Views of the United States public. Transplantation 2003; 76:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/31\">",
"      Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/32\">",
"      Jendrisak MD, Hong B, Shenoy S, et al. Altruistic living donors: evaluation for nondirected kidney or liver donation. Am J Transplant 2006; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/33\">",
"      Adams PL, Cohen DJ, Danovitch GM, et al. The nondirected live-kidney donor: ethical considerations and practice guidelines: A National Conference Report. Transplantation 2002; 74:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/34\">",
"      Ross LF, Zenios S. Restricting living-donor-cadaver-donor exchanges to ensure that standard blood type O wait-list candidates benefit. Transplantation 2004; 78:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/35\">",
"      Delmonico FL, Morrissey PE, Lipkowitz GS, et al. Donor kidney exchanges. Am J Transplant 2004; 4:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/36\">",
"      Waterman AD, Brennan DC. Improving patient education delivery to increase living donation rates. Am J Transplant 2007; 7:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31925/abstract/37\">",
"      Rodrigue JR, Cornell DL, Lin JK, et al. Increasing live donor kidney transplantation: a randomized controlled trial of a home-based educational intervention. Am J Transplant 2007; 7:394.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7311 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31925=[""].join("\n");
var outline_f31_11_31925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DONOR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF DONOR NEPHRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ALLOGRAFT OUTCOME AFTER KIDNEY DONATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXPANSION OF LIVING UNRELATED DONOR POOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25946?source=related_link\">",
"      C4d staining in renal allografts and treatment of antibody mediated rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31926="Indirect inguinal hernia in a male";
var content_f31_11_31926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Indirect inguinal hernia in a male",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This infant has a large left inguinal hernia, seen as a bulge in the inguinal canal and a swelling of the left hemiscrotum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31926=[""].join("\n");
var outline_f31_11_31926=null;
var title_f31_11_31927="Approach to the adult with fever of unknown origin";
var content_f31_11_31927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult with fever of unknown origin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     David H Bor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31927/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/11/31927/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians commonly refer to a febrile illness without an initially obvious etiology (sometimes called fever without localizing signs) as fever of unknown origin (FUO). This usage is not accurate. Most febrile illnesses either resolve before a diagnosis can be made or develop distinguishing characteristics that lead to a diagnosis. FUO refers to a prolonged febrile illness without an established etiology despite intensive evaluation and diagnostic testing.",
"   </p>",
"   <p>",
"    Large case series of FUO applying this definition have been collected over a number of decades; these facilitate an approach to patients with FUO and an understanding of the changing patterns of FUO with time and newer diagnostic techniques.",
"   </p>",
"   <p>",
"    The definitions and special populations with FUO as well as the diagnostic approach to the adult with this problem are reviewed here. A specific discussion of the common and uncommon entities causing FUO and the approach to children with FUO is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of FUO derived by Petersdorf and Beeson in 1961 from a prospective analysis of 100 cases has long been the clinical standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever higher than 38.3&ordm;C on several occasions",
"     </li>",
"     <li>",
"      Duration of fever for at least three weeks",
"     </li>",
"     <li>",
"      Uncertain diagnosis after one week of study in the hospital",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition has been used to compare and contrast FUO in different eras, geographic locales, and special patient populations (",
"    <a class=\"graphic graphic_table graphicRef54701 graphicRef66395 \" href=\"mobipreview.htm?24/27/25022\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/1-9\">",
"     1-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Refinements to the definition have been proposed, including eliminating the in-hospital evaluation requirement because of the increased sophistication of outpatient evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/10\">",
"     10",
"    </a>",
"    ]. Expansion of the definition has also been suggested to include nosocomial, neutropenic, and HIV-associated fevers that may not be prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Establishing that a patient has an FUO",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the degree and duration of fever are not the only criteria for defining an FUO. Prior to concluding that a patient has an FUO, the following evaluation should have been performed and should have been unrevealing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Complete blood count, including differential and platelet count",
"     </li>",
"     <li>",
"      Blood cultures (three sets drawn from different sites over a period of at least several hours without administering antibiotics)",
"     </li>",
"     <li>",
"      Routine blood chemistries, including liver enzymes and bilirubin",
"     </li>",
"     <li>",
"      Hepatitis serology (if liver tests abnormal)",
"     </li>",
"     <li>",
"      Urinalysis, including microscopic examination, and urine culture",
"     </li>",
"     <li>",
"      Chest radiograph",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If any signs or symptoms point to a particular organ system, further testing, imaging,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy should be pursued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three general categories of illness account for the majority of \"classic\" FUO cases and have been consistent through the decades. These categories are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Malignancies",
"     </li>",
"     <li>",
"      Connective tissue diseases (eg, vasculitis, rheumatoid arthritis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed description of common and uncommon etiologies of FUO is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Changes over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scientific and technologic advances have greatly refined and expedited the differential diagnosis and therapy of FUO (",
"    <a class=\"graphic graphic_table graphicRef54701 graphicRef66395 \" href=\"mobipreview.htm?24/27/25022\">",
"     table 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/1-9\">",
"     1-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fraction of undiagnosed FUOs dropped from over 75 percent in the 1930s to less than 10 percent in the 1950s. Since then, the fraction of FUOs that go undiagnosed has steadily increased (",
"      <a class=\"graphic graphic_figure graphicRef73878 \" href=\"mobipreview.htm?40/21/41310\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/4,7,13,14\">",
"       4,7,13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The early FUO series included few connective tissue diseases, illnesses whose characterization has benefited from careful clinical studies and developments in immunology.",
"     </li>",
"     <li>",
"      Extrapulmonary tuberculosis, solid tumors, and abdominal abscesses are now less prevalent causes due to earlier diagnosis by radiologic imaging, particularly computed tomography.",
"     </li>",
"     <li>",
"      Exploratory laparotomy has given way to imaging and percutaneous guided biopsies for diagnosis.",
"     </li>",
"     <li>",
"      Infective endocarditis, which used to be a frequent cause of FUO, has become less common with improved techniques for the isolation of organisms. In the current era, when endocarditis appears as an FUO, it is more likely to be culture-negative or caused by difficult-to-isolate organisms, such as Bartonella quintana. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=see_link\">",
"       \"Blood cultures for the detection of bacteremia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True FUOs are uncommon. This was illustrated in a report from the Netherlands in which only 73 patients were identified between December 2003 and July 2005 at a 950-bed academic referral hospital and five community hospitals comprising 2800 hospital beds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]. The authors excluded immunocompromised patients, such as those with AIDS, hypogammaglobulinemia, granulocytopenia, and glucocorticoid therapy. The following distribution of causes was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Noninfectious inflammatory diseases (eg, vasculitis, systemic lupus erythematosus, polymyalgia rheumatica) &mdash; 22 percent",
"     </li>",
"     <li>",
"      Infection &mdash; 16 percent",
"     </li>",
"     <li>",
"      Malignancy &mdash; 7 percent",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; 4 percent",
"     </li>",
"     <li>",
"      No diagnosis &mdash; 51 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Future advances in microbial diagnosis through gene amplification methods, and clarification of the pathogenesis of connective tissue diseases will continue to change the distribution of FUO.",
"   </p>",
"   <p>",
"    Practice advances have not always been helpful in diagnosing FUO. The frequent use of empiric antimicrobials, for example, can delay the diagnosis of some occult abscesses and infections, and increases the number of drug fevers. Aggressive immunosuppressive regimens, lengthy intensive care unit admissions, and the increase in multiresistant organisms as resident hospital flora have all altered the types of infections encountered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Geography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged fevers in the developing world, like those in the United States at the turn of the 20th century, include infections of worldwide distribution, such as tuberculosis, typhoid, amebic liver abscesses, and AIDS. Ease of travel has the potential to bring back to the United States and other developed countries more geographically restricted illnesses that may not be familiar to clinicians, such as malaria, brucellosis, kala azar, filariasis, schistosomiasis, or Lassa fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Illnesses contracted abroad may have incubation periods that extend for months; some infections remain latent for years and may therefore present as fevers remote from the time of travel. Individuals traveling may also become infected with organisms to which local residents are not vulnerable because of preexisting immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the wide variety of exotic diseases, the most common infections among series of FUOs have not changed over the century. These continue to include typhoid fever, tuberculosis, amebic abscesses, and malaria. Fever of unknown origin is more often caused by an atypical presentation of a common entity than by a rare disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Subpopulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different entities figure in the etiology of FUO based upon features of the population being studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of FUO vary dramatically with age. In a series of 100 children with FUO, for example, one-third were self-limited undefined viral syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, multisystem diseases such as rheumatic diseases, vasculitis including giant cell arteritis, polymyalgia rheumatica, and sarcoidosis accounted for 31 percent of cases in a review of patients with FUO over the age of 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/5\">",
"     5",
"    </a>",
"    ]. Infections accounted for 25 percent and neoplasms 12 percent of cases in this report.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of FUO in HIV-positive patients reflect the degree of immunosuppression, best measured by CD4 counts and viral load determinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/18\">",
"     18",
"    </a>",
"    ]. In one series of 79 episodes of FUO among HIV-positive patients with CD4 counts ranging from 0 to",
"    <span class=\"nowrap\">",
"     790/microL",
"    </span>",
"    and a median of",
"    <span class=\"nowrap\">",
"     40/microL,",
"    </span>",
"    79 percent were due to infections and 8 percent to malignancies; only 9 percent had no definite diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/6\">",
"     6",
"    </a>",
"    ]. Over one-half were due to mycobacteria, two-thirds of which were atypical, most commonly M. avium complex (MAC). Only lymphomas were highly represented among malignancies, particularly non-Hodgkin lymphomas. Disseminated Kaposi's sarcoma was relatively infrequent. A similar distribution was noted in another report of 59 HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with FUO in HIV-negative patients, the country in which the study is performed influences the prevalent etiologies detected. In one study from Spain, for example, 137 HIV-positive patients with fevers for at least 10 days and no diagnosis after one week in hospital underwent bone marrow biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/20\">",
"     20",
"    </a>",
"    ]. The three most common diagnoses were mycobacterial infection (18 patients with M. tuberculosis and 14 with MAC), non-Hodgkin lymphoma, and visceral leishmaniasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=see_link\">",
"     \"Fever and rash in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia-associated febrile episodes without a source are most frequently linked to bacteremia. Fungal infections replace bacterial infections in prominence after the acute period (after seven days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever of unknown origin in this population is particularly confounding since it occurs in the context of a serious underlying condition that may itself cause fever. In addition, patients are often taking a number of medications (including antimicrobials), are receiving blood products, have varying degrees of immunosuppression, and, in transplant recipients, may experience allograft rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fever, even if unexplained, usually abates with return of neutrophils. When fever persists or returns after the patient is no longer neutropenic, hepatosplenic candidiasis should be strongly considered. One group has suggested redefining FUO in neutropenia to begin after three days in order to standardize future studies of this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10071?source=see_link\">",
"     \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most critical feature of the evaluation of a patient with FUO is to take a careful history and to reassess the patient frequently. It is important to look for uncommon presentations of common diseases and to perform a detailed physical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history and physical examination, like laboratory tests, have the potential to generate valuable diagnostic clues in patients with FUO. The art of diagnosis is one of discrimination as the clinician must determine which data to glean and which clues to pursue. In the series of 73 patients from the Netherlands cited above, the authors found an average of 10.5 potential diagnostic clues per patient through their careful history and physical examination and three per patient through laboratory testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]. Eighty-one percent of these clues were misleading.",
"   </p>",
"   <p>",
"    A thorough history should include the following information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Travel",
"     </li>",
"     <li>",
"      Animal exposure (eg, pets, occupational, living on a farm)",
"     </li>",
"     <li>",
"      Immunosuppression (with the degree noted)",
"     </li>",
"     <li>",
"      Drug and toxin history, including antimicrobials",
"     </li>",
"     <li>",
"      Localizing symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subtle findings may be elicited through a careful history. Examples include: subtle changes in behavior or cognition consistent with granulomatous meningitis; jaw claudication consistent with giant cell arteritis; and nocturia consistent with prostatitis. Revisiting the history on several occasions may provide new clues in difficult cases.",
"   </p>",
"   <p>",
"    The degree of fever, nature of the fever curve, apparent toxicity, and response to antipyretics has",
"    <strong>",
"     not",
"    </strong>",
"    been found to provide enough specificity to guide the diagnosis of FUO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/21\">",
"     21",
"    </a>",
"    ]. Fever may be attenuated in older patients, and moderated by use of steroids and nonsteroidal antiinflammatory drugs. However, the course of the fever curve may be helpful in determining whether the disease is escalating or waning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of diagnostic tests may be useful in FUO. In addition to the evaluation to establish the presence of an FUO (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Establishing that a patient has an FUO'",
"    </a>",
"    above), we recommend the following minimum diagnostic evaluation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Erythrocyte sedimentation rate or C-reactive protein",
"     </li>",
"     <li>",
"      Serum lactate dehydrogenase",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"      or interferon-gamma release assay (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"       \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=see_link\">",
"       \"Interferon-gamma release assays for diagnosis of latent tuberculosis infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HIV antibody assay and HIV viral load for patients at high risk (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"       \"Acute and early HIV infection: Treatment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Three routine blood cultures drawn from different sites over a period of at least several hours without administering antibiotics, if not already performed",
"     </li>",
"     <li>",
"      Rheumatoid factor",
"     </li>",
"     <li>",
"      Creatine phosphokinase",
"     </li>",
"     <li>",
"      Heterophile antibody test in children and young adults",
"     </li>",
"     <li>",
"      Antinuclear antibodies",
"     </li>",
"     <li>",
"      Serum protein electrophoresis",
"     </li>",
"     <li>",
"      CT scan of abdomen",
"     </li>",
"     <li>",
"      CT scan of chest",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most of these tests, the false positive rate, which can lead to unnecessary investigations, is similar to the rate of a helpful result. This was illustrated in the series cited above of 73 patients from the Netherlands seen between December 2003 and July 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest x-ray &mdash; performed in 73 patients: helpful in six and false positive in eight (8 and 11 percent, respectively)",
"     </li>",
"     <li>",
"      Chest CT &mdash; performed in 46 patients: helpful in nine and false positive in eight (20 and 17 percent, respectively)",
"     </li>",
"     <li>",
"      Abdominal CT &mdash; performed in 60 patients: helpful in 12 and false positive in 17 (20 and 28 percent, respectively)",
"     </li>",
"     <li>",
"      PET scan &mdash; performed in 70 patients: helpful in 23 and false positive in 10 (33 and 14 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Erythrocyte sedimentation rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians favor obtaining an erythrocyte sedimentation rate (ESR), despite its lack of specificity. One study reviewed elevations above 100",
"    <span class=\"nowrap\">",
"     mm/h",
"    </span>",
"    among 263 patients with FUO: 58 percent had malignancy, most commonly lymphoma, myeloma, or metastatic colon or breast cancer, and 25 percent had infections such as endocarditis or inflammatory diseases like rheumatoid arthritis or giant cell arteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of the ESR seems to have its greatest use in establishing a serious underlying cause of FUO, although drug hypersensitivity reactions, thrombophlebitis, and renal disease, particularly the nephrotic syndrome, may be accompanied by a very high ESR in the absence of infection or malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20081?source=see_link\">",
"     \"Erythrocyte sedimentation rate in renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A normal ESR also suggests that a significant inflammatory process, of whatever origin, is absent. Once again, however, there are exceptions. As an example, some patients with giant cell arteritis have a normal ESR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     CT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scanning of the abdomen has nearly replaced exploratory laparotomy and other radiographic tests in the search for occult abscesses or hematomas in patients with FUO. The finding of abdominal lymphadenopathy can be a clue to lymphoma or a granulomatous process. The usefulness of CT has resulted in this examination being used in nearly all patients with FUO. While MRI scan can be more sensitive in certain settings, eg, the diagnosis of spinal epidural abscess, it is rarely required in the initial evaluation of FUO.",
"   </p>",
"   <p>",
"    For similar reasons, CT scanning of the chest is invaluable in the identification of small nodules (indicative of fungal, mycobacterial, or nocardial infection or malignancy). The identification of hilar or mediastinal adenopathy may prompt biopsy by mediastinoscopy providing a diagnosis of lymphoma, histoplasmosis, or sarcoidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nuclear medicine testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclear medicine testing is a more controversial area in the diagnosis of FUO. Both gallium-67 and indium-111 labeled leukocyte scanning are highly sensitive by virtue of including the whole body. Neither study, however, can pinpoint a diagnosis; as a result, they are nonspecific tests to localize a site for more specific evaluation such as with CT. When studied, the overall yield of gallium-67 or indium-111 labeled leukocyte scanning may be higher than with computed tomography (CT) or ultrasound, since the latter tests focus on only a few parts of the body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In one study of 145 cases of FUO, for example, 29 percent of the gallium-67 scans were helpful in establishing a diagnosis, versus 6 and 14 percent of ultrasound examinations and CT scans, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of FUO in the elderly found that gallium scanning had a diagnostic contribution in 17 of 47 cases, while 11 were thought to be false positives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/5\">",
"     5",
"    </a>",
"    ]. This study recommended gallium scanning as the next step after routine laboratory tests, temporal artery biopsy, and abdominal ultrasonography in this population.",
"   </p>",
"   <p>",
"    F-fluorodeoxyglucose positron emission tomography (FDG-PET) appears to be very sensitive in identifying anatomic sites of inflammation and malignancy. This modality may find a valuable place in the evaluation of FUO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/26\">",
"     26",
"    </a>",
"    ], but data demonstrating efficacy are needed.",
"   </p>",
"   <p>",
"    We recommend an abdominal and chest CT as part of the routine evaluation of FUO, reserving nuclear medicine imaging for cases in which the initial evaluation remains negative and a screening look at the entire body is desired. As noted above, however, the rate of false positive tests with these modalities is similar to the rate of a positive result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Test performance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the history, examination, or imaging uncovers a possible source, specific testing should be performed. Subtle central nervous system symptoms or signs, for example, should prompt a lumbar puncture and imaging of the head",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spine. In the United States, a travel history to the Midwest or the deserts of the West should raise the question of a fungal process like histoplasmosis or coccidioidomycosis, respectively. Serologic testing in individuals who have not resided in an endemic area can be useful. A history of trauma or adjacent infection may suggest thrombophlebitis of the legs, arms, or pelvic vessels. Venous duplex imaging can be diagnostic. Fever usually responds to anticoagulation within several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is a critical modality in the directed (as opposed to screening) evaluation of FUO. The following examples include data from the Netherlands study of 73 patients cited above on the utility of biopsy of different sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver biopsy for possible miliary tuberculosis, granulomatous hepatitis, or other granulomatous diseases such as sarcoidosis &mdash; liver biopsy was performed in seven patients; it was helpful in one and false positive in three.",
"     </li>",
"     <li>",
"      Lymph node biopsy for possible malignancy, especially lymphoma, or infections such as cat-scratch disease &mdash; lymph node biopsy was performed in 11 patients; it was helpful in five and false positive in three.",
"     </li>",
"     <li>",
"      Temporal artery to look for giant cell arteritis or biopsy of an affected tissue to diagnose a vasculitic process such as polyarteritis nodosa &mdash; temporal artery biopsy was performed in 14 patients; it was helpful in one with no false positives.",
"     </li>",
"     <li>",
"      Pleural or pericardial biopsy in the evaluation of extrapulmonary tuberculosis.",
"     </li>",
"     <li>",
"      Bone marrow biopsy was performed in 19 patients; it was helpful in two and false positive in one.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective review of 31 diagnostic bone marrow biopsies obtained to evaluate FUOs at a French tertiary hospital, occult hematologic malignancies were detected in 25 patients; lymphoma was detected in 19 patients, acute leukemia in four patients, hairy cell leukemia in one patient, and multiple myeloma in one patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/27\">",
"     27",
"    </a>",
"    ]. Among those with non-malignant causes, infections were detected in three patients, systemic mastocytosis in two patients, and disseminated granulomatosis in one patient. Thrombocytopenia and anemia strongly predicted a diagnostic biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Therapeutic trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic trials of antimicrobials or glucocorticoids, while tempting in the effort to \"do something,\" rarely establish a diagnosis. In addition, the diagnostic yield of blood cultures and cultures of biopsy material will be reduced following the initiation of antibiotics. Antimicrobial agents could be expected to suppress, but not cure, an infectious process such as an occult abscess since adjunctive drainage would usually be required.",
"   </p>",
"   <p>",
"    Antibiotics can have effects on other infections than the ones to which therapy is directed.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    , for example, used in a therapeutic trial for tuberculosis may suppress staphylococcal osteomyelitis or diminish the ability to detect difficult to isolate organisms causing endocarditis. The appropriate duration of a therapeutic trial is also unclear since a number of infections such as endocarditis or pelvic inflammatory disease can take as much as one week for fever to abate, even with appropriate therapy. Thus, patients with FUO should not have empiric antibiotics started solely to treat fever.",
"   </p>",
"   <p>",
"    A therapeutic trial of glucocorticoids for an inflammatory process should not replace relevant biopsies for steroid-responsive disease such as sarcoidosis, other granulomatous diseases, or vasculitis. A careful evaluation for infection should precede such a trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     No diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of no diagnosis in studies of FUO published since 1990 has varied widely from 9 to 51 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. As described in the following section, most of these patients do well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of patients with an FUO depends upon the underlying diagnosis. Among children with FUO, 88 percent of those caused by infections have no sequelae.",
"   </p>",
"   <p>",
"    Most adults who remain undiagnosed after an extensive evaluation also have a good prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/7,8,28\">",
"     7,8,28",
"    </a>",
"    ]. This was illustrated in a study of 199 patients with FUO, 61 of whom (30 percent) were discharged from the hospital without a diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A definite diagnosis was established in 12, usually within two months after discharge.",
"     </li>",
"     <li>",
"      Thirty-one became symptom-free during hospitalization or shortly following discharge.",
"     </li>",
"     <li>",
"      Eighteen had persisting or recurring fever for several months or even years after discharge, 10 of who were considered to be finally cured.",
"     </li>",
"     <li>",
"      Four were treated with glucocorticoids and six required intermittent therapy with nonsteroidal antiinflammatory drugs.",
"     </li>",
"     <li>",
"      Six died, but the cause of death was considered to be related to the disease that caused FUO in only two cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in the Netherlands series of 73 patients cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"     9",
"    </a>",
"    ]. Among the 37 patients with no diagnosis who were followed for at least six months, 16 spontaneously recovered, 5 recovered with nonsteroidal antiinflammatory drugs or glucocorticoids, 15 had persistent fever, and 1 died.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever of unknown origin (FUO) is defined as fever higher than 38.3&ordm;C on several occasions lasting for at least three (some use two) weeks without an established etiology despite intensive evaluation and diagnostic testing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three general categories of illness account for the majority of \"classic\" FUO cases and have been consistent through the decades. These categories are infections, malignancies, and connective tissue diseases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of specific etiologic agents of FUO varies by age of the population, by potential exposure to infectious agents, by host susceptibility to infection, and over time with advances in diagnostics in identifying the etiologic agent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important aspects of the evaluation of a patient with FUO are to take a careful history, perform a detailed physical examination, and to reassess the patient frequently. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'History and physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend the following minimum diagnostic evaluation: blood cultures, erythrocyte sedimentation rate or C-reactive protein, serum lactate dehydrogenase, HIV antibody test and viral load, rheumatoid factor, heterophile antibody test, creatine phosphokinase, antinuclear antibodies,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      or interferon-gamma release assay, serum protein electrophoresis, and computed tomography scan of abdomen and chest. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary evaluation and diagnostic workup can suggest a directed biopsy that may establish the diagnosis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation may fail to identify an etiology in as many as 30 to 50 percent of patients. Most adults who remain undiagnosed have a good prognosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/1\">",
"      PETERSDORF RG, BEESON PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/2\">",
"      Alt HL, Barker MH. Fever of unknown origin. JAMA 1930; 94:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/3\">",
"      Jacoby GA, Swartz MN. Fever of undetermined origin. N Engl J Med 1973; 289:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/4\">",
"      de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997; 76:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/5\">",
"      Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993; 41:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/6\">",
"      Miller RF, Hingorami AD, Foley NM. Pyrexia of undetermined origin in patients with human immunodeficiency virus infection and AIDS. Int J STD AIDS 1996; 7:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/7\">",
"      Vanderschueren S, Knockaert D, Adriaenssens T, et al. From prolonged febrile illness to fever of unknown origin: the challenge continues. Arch Intern Med 2003; 163:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/8\">",
"      Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital. Scand J Infect Dis 2006; 38:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/9\">",
"      Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore) 2007; 86:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/10\">",
"      Petersdorf RG. Fever of unknown origin. An old friend revisited. Arch Intern Med 1992; 152:21.",
"     </a>",
"    </li>",
"    <li>",
"     Durack DT, Street AC. Fever of unknown origin: Re-examined and redefined. In: Current Clinical Topics in Infectious Diseases, Remington JS, Swartz MN (Eds), Blackwell Science, Boston 1991. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/12\">",
"      Konecny P, Davidson RN. Pyrexia of unknown origin in the 1990s: time to redefine. Br J Hosp Med 1996; 56:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/13\">",
"      Mourad O, Palda V, Detsky AS. A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med 2003; 163:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/14\">",
"      Horowitz HW. Fever of unknown origin or fever of too many origins? N Engl J Med 2013; 368:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/15\">",
"      Sharma BK, Kumari S, Varma SC, et al. Prolonged undiagnosed fever in northern India. Trop Geogr Med 1992; 44:32.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson ME. Chapter 5. In: A World Guide to Infections: Diseases, Distribution, Diagnosis, Oxford University Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/17\">",
"      Pizzo PA, Lovejoy FH Jr, Smith DH. Prolonged fever in children: review of 100 cases. Pediatrics 1975; 55:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/18\">",
"      Sullivan M, Feinberg J, Bartlett JG. Fever in patients with HIV infection. Infect Dis Clin North Am 1996; 10:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/19\">",
"      Bissuel F, Leport C, Perronne C, et al. Fever of unknown origin in HIV-infected patients: a critical analysis of a retrospective series of 57 cases. J Intern Med 1994; 236:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/20\">",
"      Benito N, N&uacute;&ntilde;ez A, de G&oacute;rgolas M, et al. Bone marrow biopsy in the diagnosis of fever of unknown origin in patients with acquired immunodeficiency syndrome. Arch Intern Med 1997; 157:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/21\">",
"      Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis 1997; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/22\">",
"      Zacharski LR, Kyle RA. Significance of extreme elevation of erythrocyte sedimentation rate. JAMA 1967; 202:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/23\">",
"      Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996; 35:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/24\">",
"      Knockaert DC, Mortelmans LA, De Roo MC, Bobbaers HJ. Clinical value of gallium-67 scintigraphy in evaluation of fever of unknown origin. Clin Infect Dis 1994; 18:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/25\">",
"      Syrj&auml;l&auml; MT, Valtonen V, Liewendahl K, Myllyl&auml; G. Diagnostic significance of indium-111 granulocyte scintigraphy in febrile patients. J Nucl Med 1987; 28:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/26\">",
"      Bleeker-Rovers CP, Vos FJ, Mudde AH, et al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007; 34:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/27\">",
"      Hot A, Jaisson I, Girard C, et al. Yield of bone marrow examination in diagnosing the source of fever of unknown origin. Arch Intern Med 2009; 169:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31927/abstract/28\">",
"      Knockaert DC, Dujardin KS, Bobbaers HJ. Long-term follow-up of patients with undiagnosed fever of unknown origin. Arch Intern Med 1996; 156:618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2736 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-113.53.254.124-C33D2BEBF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31927=[""].join("\n");
var outline_f31_11_31927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Establishing that a patient has an FUO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Changes over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Geography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Subpopulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - AIDS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Erythrocyte sedimentation rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - CT scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nuclear medicine testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Therapeutic trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      No diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2736\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2736|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/21/41310\" title=\"figure 1\">",
"      Causes of FUO over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2736|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/24/8589\" title=\"table 1A\">",
"      Case studies of FUO I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/47/22269\" title=\"table 1B\">",
"      Case studies of FUO II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11494?source=related_link\">",
"      Blood cultures for the detection of bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20081?source=related_link\">",
"      Erythrocyte sedimentation rate in renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15431?source=related_link\">",
"      Etiologies of fever of unknown origin in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37160?source=related_link\">",
"      Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31928="Pharmacologic and supportive interventions for croup";
var content_f31_11_31928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic and supportive interventions for croup",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Charles R Woods, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31928/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/11/31928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Croup (laryngotracheitis) is a respiratory illness characterized by inspiratory stridor, barking cough, and hoarseness. It typically occurs in children six months to three years of age and is caused by parainfluenza virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link\">",
"     \"Clinical features, evaluation, and diagnosis of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of croup has changed significantly since the 1980s. Glucocorticoids and nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    have become the cornerstones of therapy. Substantial clinical evidence supports the efficacy of these interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The impact also is evident in the decrease in annual hospital admissions for croup in children in the United States between 1979 to 1982 and 1994 to 1997 (from 2.8 to 2.1 per 1000 for children &lt;1 year and from 1.8 to 1.2 per 1000 children for children 1 to 4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of croup may involve a variety of pharmacologic and nonpharmacologic interventions. It may occur entirely at home, or in the office, emergency department (ED), or hospital setting. Supportive and pharmacologic interventions will be discussed below. The clinical features and evaluation of croup and the approach to management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link\">",
"     \"Clinical features, evaluation, and diagnosis of croup\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link\">",
"     \"Approach to the management of croup\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids provide long-lasting and effective treatment of mild, moderate, and severe croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/3,7-9\">",
"     3,7-9",
"    </a>",
"    ]. The antiinflammatory actions of glucocorticoids are thought to decrease edema in the laryngeal mucosa of children with croup. Improvement is usually evident within six hours of administration but seldom is dramatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with glucocorticoids at various doses and by various routes has been shown to improve croup scores and to decrease unscheduled medical visits, length of stay in the emergency department or hospital, and the use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"     7",
"    </a>",
"    ]. Among the available glucocorticoids,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been used most frequently, is the least expensive, has the longest duration of action, and is the easiest to administer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular (IM), intravenous (IV), oral, and inhaled routes of administration of glucocorticoids have been shown to be effective in croup of all levels of severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    (oral or IM) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    (inhaled) were the agents used in the majority of studies. A systematic review included 24 trials (with collective enrollment of 2878 children) that objectively measured the effectiveness of glucocorticoid treatment for croup compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"     7",
"    </a>",
"    ]. Fourteen other trials compared different glucocorticoid agents or different routes or dosages of the same agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"     7",
"    </a>",
"    ]. Compared with treatment with placebo, treatment with glucocorticoid was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in the croup score at six hours with a weighted mean difference of -1.2 (95% CI -1.6 to -0.8) and at 12 hours -1.9 (95% CI -2.4 to -1.3); at 24 hours this improvement was no longer significant (-1.3, 95% CI -2.7-0.2)",
"     </li>",
"     <li>",
"      Fewer return visits",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      (re)admissions (relative risk 0.50, 95% CI 0.3-0.7)",
"     </li>",
"     <li>",
"      Decreased length of time spent in emergency department or hospital (weighted mean difference 12 hours, 95% CI 5-19 hours)",
"     </li>",
"     <li>",
"      Decreased use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      (risk difference 10 percent; 95% CI 1-20 percent)",
"     </li>",
"     <li>",
"      There were no significant differences in clinical efficacy between the routes or agents, and the combination of oral or IM",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      with inhaled",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"       budesonide",
"      </a>",
"      was not superior to either agent alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another systematic review of eight randomized controlled trials compared the administration of nebulized glucocorticoids with placebo. Children treated with nebulized glucocorticoids were significantly more likely to show improvement in croup score at five hours (combined relative risk (RR) 1.48, 95% CI 1.27-1.74) and significantly less likely to need hospital admission (combined RR 0.56, 95% CI 0.42-0.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few serious adverse effects have been reported in the studies evaluating the efficacy of a",
"    <strong>",
"     single",
"    </strong>",
"    dose of glucocorticoids in croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14\">",
"     14",
"    </a>",
"    ]. However, most of these studies were too small to sufficiently evaluate rare (&lt;1 percent) adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary concern is potential risk of progressive viral infection or secondary bacterial infection, which have been reported in patients who received glucocorticoid treatment over several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/15\">",
"     15",
"    </a>",
"    ], or received nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and had neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/17\">",
"     17",
"    </a>",
"    ]. These complications have not been described in children who have received single doses of oral, intramuscular, or intravenous glucocorticoids for croup.",
"   </p>",
"   <p>",
"    Glucocorticoid use may exacerbate active varicella and tuberculosis and should be avoided in children with these infections and in those recently exposed to, and possibly incubating, varicella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=see_link\">",
"     \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of glucocorticoids may mask the presentation of steroid-responsive upper airway lesions, such as hemangiomas, which also can present with stridor, particularly during a viral upper respiratory tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    may be administered IM, IV, or orally. To date, no clinically significant difference in croup outcomes between IM or orally administered dexamethasone has been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"     7",
"    </a>",
"    ]. When dexamethasone is administered IM or IV, a single dose of 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum dose of 10 mg) is used most frequently. Smaller doses appear to be equally effective for mild croup when administered orally, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 100 children with mild croup were randomly assigned to receive oral",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or placebo in the emergency department [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/21\">",
"       21",
"      </a>",
"      ]. Eight children in the placebo group, and none in the dexamethasone group, returned for medical care (a statistically significant difference).",
"     </li>",
"     <li>",
"      In another study, 120 hospitalized children with croup were randomly assigned to receive a single oral dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      0.3",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      0.6",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/22\">",
"       22",
"      </a>",
"      ]. There was no difference in duration of hospitalization, reduction in croup score, or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      use among the three groups receiving dexamethasone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second study described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/22\">",
"     22",
"    </a>",
"    ] included a small number of children with relatively mild croup and consequently may have been underpowered (unable) to detect a clinically important difference, particularly in children with more severe symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with mild croup who can tolerate oral medications can be given either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or dexamethasone 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally, to a maximum total dose of 10 mg. Although the lower 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose appears to be efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/21\">",
"     21",
"    </a>",
"    ], we continue to suggest the higher dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The higher dose can be given all at once or divided into four doses over 24 hours if desired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral preparation of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (1 mg per mL) has a foul taste. The intravenous preparation is more concentrated (4 mg per mL) and can be given orally mixed with syrup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/11,24-26\">",
"     11,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in children with croup have mixed results. One study found nebulized dexamethasone to be less effective than oral dexamethasone in preventing the need for subsequent treatment with glucocorticoid or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    in children with mild croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/27\">",
"     27",
"    </a>",
"    ]. Another study found that treatment with nebulized dexamethasone in children with moderate croup improved croup scores at four hours but did not affect the rate of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, two patients with neutropenia who were treated with dexamethasone developed bacterial tracheitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Budesonide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    has been shown to be more effective than placebo and as effective as IM or oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the treatment of croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7,28\">",
"     7,28",
"    </a>",
"    ]. However, nebulized budesonide is more expensive and more difficult to administer than IM or oral dexamethasone and is not routinely indicated in the treatment of croup. However, nebulized budesonide may provide an alternative to IM or IV dexamethasone for children with vomiting or severe respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/24\">",
"     24",
"    </a>",
"    ]. In children with severe respiratory distress, a single dose of budesonide may be mixed with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    and administered simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the management of croup\", section on 'Moderate to severe croup'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prednisolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    in the treatment of croup has been evaluated in a limited number of studies, described below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared a single oral dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      to a single oral dose of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      in 133 children with mild to moderate croup [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/29\">",
"       29",
"      </a>",
"      ]. Compared with those who received dexamethasone, those who received prednisolone were more likely to present for unscheduled medical care in the following 7 to 10 days (29 versus 7 percent). There were no significant differences in secondary outcome measures: croup score,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      usage, time spent in the emergency department, duration of croup, and viral symptoms.",
"     </li>",
"     <li>",
"      Another study of 70 children compared",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours) with placebo in children with croup who were already intubated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/8\">",
"       8",
"      </a>",
"      ]. Children who received prednisolone had a shorter median duration of intubation than those in the placebo group (98 versus 138 hours). In addition, fewer children in the prednisolone group required reintubation (5 versus 34 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some authorities suggest that for children who are treated as outpatients, oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses for two days) is an alternative to oral",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/23\">",
"     23",
"    </a>",
"    ]. Meta-analysis of two studies that compared oral dexamethasone with oral prednisolone showed no difference in croup scores, but children randomized to receive dexamethasone had fewer return visits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subsequent admissions (9.6 versus 29.7 percent, RR 0.3, 95% CI 0.2-0.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    in the management of croup has not been evaluated in clinical trials. However, it has equivalent potency to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    and, in theory, should have similar effects. Despite its lack of proven benefit, prednisone is widely used in the outpatient management of croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    is to be used, it is important to administer a dose that is equivalent in strength to the doses of glucocorticoids that have been better studied.",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    has 6.67 times the glucocorticoid potency of prednisone (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone = 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of dexamethasone; 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone = 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of dexamethasone; and 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone = 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of dexamethasone). If choosing to use the higher dose (ie, 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of prednisone), the volume required may be prohibitive given that the concentration of the oral solution of prednisone is 1",
"    <span class=\"nowrap\">",
"     mg/1",
"    </span>",
"    mL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Betamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study compared the effectiveness of a single oral dose of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/7/28791?source=see_link\">",
"     betamethasone",
"    </a>",
"    (0.4",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    with a single dose of IM",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (0.6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    in 52 children (six months to six years) with mild to moderate croup who were treated in the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/31\">",
"     31",
"    </a>",
"    ]. Despite randomization, mean baseline croup scores were higher in the dexamethasone group (3.6 versus 2). Croup scores declined significantly in both groups, and there were no differences between groups in mean croup scores four hours after treatment, rate of hospitalization, time to resolution of symptoms, need for additional treatment, or number of return visits to the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Repeated dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of clinical trials of oral and IM glucocorticoids in croup have used a single dose. Repeat doses are not necessary on a routine basis. Although repeat doses may be reasonable in the occasional child who has persistent symptoms, they should be used with caution. The anecdotal cases of progression of viral illness and secondary bacterial infection that have been reported with use of glucocorticoids for croup occurred with repeated dosing over several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/32\">",
"     32",
"    </a>",
"    ], or in neutropenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Moderate to severe symptoms that persist for more than a few days should prompt investigation for other causes of airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features, evaluation, and diagnosis of croup\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NEBULIZED EPINEPHRINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    to patients with moderate to severe croup often results in rapid improvement of upper airway obstruction. Epinephrine constricts precapillary arterioles in the upper airway mucosa and decreases capillary hydrostatic pressure, leading to fluid resorption and improvement in airway edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/18\">",
"     18",
"    </a>",
"    ]. Even a modest increase in airway diameter can lead to significant clinical improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small randomized controlled trials and a meta-analysis have demonstrated the benefit of racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    compared with placebo in reducing the croup scores 30 minutes after treatment in children in the emergency department, hospital, and intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1,33-35\">",
"     1,33-35",
"    </a>",
"    ]. The magnitude of reduction in mean croup score from baseline ranged from 2.2 to 3.6 at 20 to 30 minutes (compared with approximately 1 in the placebo group). However, by 120 minutes, croup scores returned to baseline or near baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1,34\">",
"     1,34",
"    </a>",
"    ]. In one trial, treatment with IM",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and nebulized epinephrine was associated with decreased duration of hospitalization compared with IM dexamethasone and placebo (-32 hours, 95% CI -59.1 to -4.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    does not alter the natural history of croup in the short (&gt;2 hours) or longer term (24 to 36 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1,34,36\">",
"     1,34,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the studies described above, racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    was administered either by nebulization alone or by nebulization combined with intermittent positive pressure breaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ]. Another study compared these two methods of administration and found them to be similarly effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18926277\">",
"    <span class=\"h2\">",
"     Racemic versus&nbsp;L-epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    , which is a 1:1 mixture of the D- and L-isomers, was initially thought to produce fewer systemic side effects, such as tachycardia and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/18\">",
"     18",
"    </a>",
"    ]. However, a prospective randomized double-blind study comparing racemic epinephrine and L-epinephrine in children with croup found no difference between the two preparations in 30-minute croup score, heart rate, blood pressure, respiratory rate, fraction of inspired oxygen, or oxygen saturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/38\">",
"     38",
"    </a>",
"    ]. This finding is particularly important outside of the United States, where racemic epinephrine is not readily available. Either form of epinephrine is acceptable to use in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Racemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      is administered as 0.05",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per dose (maximum of 0.5 mL) of a 2.25 percent solution diluted to 3 mL total volume with normal saline. It is given via nebulizer over 15 minutes.",
"     </li>",
"     <li>",
"      L-",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      is administered as 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per dose (maximum of 5 mL) of a 1:1000 dilution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/38\">",
"       38",
"      </a>",
"      ]. It is given via nebulizer over 15 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    treatments may be repeated every 15 to 20 minutes if warranted by the clinical course. Children who require repeated frequent dosing (eg, three or more doses within two to three hours) to achieve stabilization of their respiratory function generally should be admitted to an intensive care unit or intermediate care setting (depending on the severity of persisting signs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical effects of nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    last for no more than two hours. After the effects have worn off, symptoms may return to baseline (an apparent worsening, sometimes referred to as the \"rebound phenomenon\"). Children who receive even a single dose of nebulized epinephrine should be observed in the emergency department or hospital setting for at least three to four hours after administration to ensure that symptoms do not return to baseline.",
"   </p>",
"   <p>",
"    Serious adverse effects from nebulized",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    are exceedingly rare. However, a case of myocardial infarction in a child with croup who received three doses of racemic epinephrine within 60 minutes has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, it seems prudent to place children who require ongoing epinephrine treatments more frequently than every one to two hours on cardiac monitors (both because of the severity of illness and the potential systemic impact of nebulized epinephrine). Continuous electrocardiographic monitoring (or equivalent cardiac monitoring) also should be considered in these cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OXYGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen is not known to have any direct impact on the subglottic edema or airway narrowing, but should be administered to children who are hypoxemic (oxygen saturation of &lt;92 percent in room air)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in moderate to severe respiratory distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14,24\">",
"     14,24",
"    </a>",
"    ]. Supplemental oxygen should be humidified to decrease drying effects on the airways, since drying may impede the physiologic removal of airway secretions via mucociliary and cough mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Heliox",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helium is inert, nontoxic, and of very low density. Heliox is a mixture of helium (70 to 80 percent) and oxygen (20 to 30 percent). It can flow through airways with less turbulence and resistance than pure oxygen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heliox decreases the work of respiration in children with croup and theoretically could be used as a temporizing measure, to prevent the need for intubation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/40\">",
"     40",
"    </a>",
"    ] while waiting for glucocorticoids to decrease airway edema. However, in clinical trials, heliox has not been shown to be more effective than humidified oxygen or racemic",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    in reducing croup scores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. The two randomized trials that have addressed this issue evaluated a total of only 44 patients. A 2010 systematic review concluded that a larger trial is needed before further recommendations for use or avoidance of heliox can be made for croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MIST THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humidified air is frequently used in the treatment of croup, although there have been no studies supporting its efficacy in reducing symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/44\">",
"     44",
"    </a>",
"    ]. Two randomized trials (one comparing mist versus no mist and the other comparing no mist, low humidity, and 100 percent humidity) among children brought to an emergency department for croup demonstrated no significant change in croup scores from baseline between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although humidified air does not reduce subglottic edema, it may provide other benefits. Inhalation of moist air, relative to dry air, may decrease drying of inflamed mucosal surfaces and reduce inspissation of secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition, a mist source may provide a sense of comfort and reassurance to both the child and family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In medical settings, mist therapy may be provided by blow-by or saline nebulization treatments. Croup tents should be avoided, since they can aggravate a child's anxiety and make vital signs and other visual assessments of the child more difficult. Some guidelines recommend against the use of mist therapy for children who are hospitalized with croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/24\">",
"     24",
"    </a>",
"    ]. Certainly if the child is agitated by the provision of mist, mist therapy should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics have no role in the routine management of uncomplicated croup, since most cases are caused by viruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14\">",
"     14",
"    </a>",
"    ]. Antibiotics should be used only to treat specific bacterial complications, such as tracheitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antitussives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonprescription antitussive agents are of unproven benefit for croup (or other respiratory tract infections).",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32230?source=see_link\">",
"     Codeine",
"    </a>",
"    , which is a more potent cough suppressant, can alter the child's sensorium, making it difficult to follow the clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Decongestants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decongestants also are of unproven benefit for croup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14,24\">",
"     14,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sedatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedative agents may improve airway obstruction by relieving anxiety and apprehension. However, their routine use is not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/24\">",
"     24",
"    </a>",
"    ]. Sedatives may treat the symptom of agitation while masking the underlying causes of air hunger and hypoxia. They also may decrease respiratory effort (and therefore croup scores), without improving ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14,51\">",
"     14,51",
"    </a>",
"    ]. Judicious use of sedatives in an intensive care setting (with close monitoring of respiratory function) in an effort to avoid intubation may be reasonable, although evidence demonstrating the benefit of this strategy is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/63/32754?source=see_link\">",
"       \"Patient information: Croup (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=see_link\">",
"       \"Patient information: Croup in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with glucocorticoids (oral, intramuscular, or nebulized) has been shown to decrease croup scores, unscheduled medical visits, length of stay in the emergency department or hospital, and the use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment with nebulized",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      results in rapid improvement of upper airway obstruction, but the duration of effect is less than two hours. Racemic epinephrine and L-epinephrine appear to be equally effective. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Nebulized epinephrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humidified air is frequently used as a supportive treatment for croup; however, there have been no studies supporting its efficacy in reducing symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mist therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humidified oxygen should be administered to children who are hypoxemic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in moderate to severe respiratory distress. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Oxygen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heliox has not been shown to be more effective than humidified oxygen or racemic",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      in reducing croup scores. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Heliox'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics should be used only to treat specific bacterial complications of croup. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antibiotics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=see_link&amp;anchor=H25#H25\">",
"       \"Approach to the management of croup\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antitussives and decongestants are of unproven benefit in the management of croup. Sedatives may decrease the work of breathing and improve agitation without actually improving ventilation or addressing the underlying cause of agitation (hypoxemia). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/1\">",
"      Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978; 132:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/2\">",
"      Fogel JM, Berg IJ, Gerber MA, Sherter CB. Racemic epinephrine in the treatment of croup: nebulization alone versus nebulization with intermittent positive pressure breathing. J Pediatr 1982; 101:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/3\">",
"      Kairys SW, Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials. Pediatrics 1989; 83:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/4\">",
"      Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med 1998; 339:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/5\">",
"      Klassen TP, Feldman ME, Watters LK, et al. Nebulized budesonide for children with mild-to-moderate croup. N Engl J Med 1994; 331:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/6\">",
"      Counihan ME, Shay DK, Holman RC, et al. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001; 20:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/7\">",
"      Russell KF, Liang Y, O'Gorman K, et al. Glucocorticoids for croup. Cochrane Database Syst Rev 2011; :CD001955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/8\">",
"      Tibballs J, Shann FA, Landau LI. Placebo-controlled trial of prednisolone in children intubated for croup. Lancet 1992; 340:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/9\">",
"      Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild croup. N Engl J Med 2004; 351:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/10\">",
"      Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatr Pulmonol 1995; 20:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/11\">",
"      Klassen TP, Craig WR, Moher D, et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. JAMA 1998; 279:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/12\">",
"      Geelhoed GC. Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup. Pediatr Emerg Care 2005; 21:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/13\">",
"      Griffin S, Ellis S, Fitzgerald-Barron A, et al. Nebulised steroid in the treatment of croup: a systematic review of randomised controlled trials. Br J Gen Pract 2000; 50:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/14\">",
"      Johnson D. Croup. Clin Evid 2005; :310.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry, JD. Croup (Laryngitis, laryngotracheitis, spasmodic croup, laryngotracheobronchitis, bacterial tracheitis, and laryngotracheobronchopneumonitis). In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin, RD, Cherry, JD, Demmler-Harrison, GJ, Kaplan, SL (Eds), Saunders, Philadelphia, 2009. p. 254.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/16\">",
"      Vernacchio L, Mitchell AA. Oral dexamethasone for mild croup. N Engl J Med 2004; 351:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/17\">",
"      Johnson DW, Schuh S, Koren G, Jaffee DM. Outpatient treatment of croup with nebulized dexamethasone. Arch Pediatr Adolesc Med 1996; 150:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/18\">",
"      Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J 1998; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/19\">",
"      Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics 1993; 92:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/20\">",
"      Kiff KM, Mok Q, Dunne J, Tasker RC. Steroids for intubated croup masking airway haemangioma. Arch Dis Child 1996; 74:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/21\">",
"      Geelhoed GC, Turner J, Macdonald WB. Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial. BMJ 1996; 313:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/22\">",
"      Geelhoed GC, Macdonald WB. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995; 20:362.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher, G. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher, GR, Ludwig, S, Henretig, FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p. 783.",
"    </li>",
"    <li>",
"     Alberta Clinical Practice Guidelines Guideline Working Group. Guidelines to the diagnosis and management of croup. Available at: www.albertadoctors.org/bcm/ama/ama-website.nsf/AllDoc/87256DB000705C3F87256E05005534E2/$File/CROUP.PDF (Accessed on January 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/25\">",
"      Paul, RI. Oral dexamethasone for croup (commentary). AAP Grand Rounds 2004; 12:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/26\">",
"      Duggan DE, Yeh KC, Matalia N, et al. Bioavailability of oral dexamethasone. Clin Pharmacol Ther 1975; 18:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/27\">",
"      Luria JW, Gonzalez-del-Rey JA, DiGiulio GA, et al. Effectiveness of oral or nebulized dexamethasone for children with mild croup. Arch Pediatr Adolesc Med 2001; 155:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/28\">",
"      Cetinkaya F, T&uuml;fek&ccedil;i BS, Kutluk G. A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. Int J Pediatr Otorhinolaryngol 2004; 68:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/29\">",
"      Sparrow A, Geelhoed G. Prednisolone versus dexamethasone in croup: a randomised equivalence trial. Arch Dis Child 2006; 91:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/30\">",
"      Connors K, Gavula D, Terndrup T. The use of corticosteroids in croup: a survey. Pediatr Emerg Care 1994; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/31\">",
"      Amir L, Hubermann H, Halevi A, et al. Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup: a prospective, randomized trial. Pediatr Emerg Care 2006; 22:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/32\">",
"      Cherry JD. State of the evidence for standard-of-care treatments for croup: are we where we need to be? Pediatr Infect Dis J 2005; 24:S198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/33\">",
"      Kristj&aacute;nsson S, Berg-Kelly K, Wins&ouml; E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/34\">",
"      Taussig LM, Castro O, Beaudry PH, et al. Treatment of laryngotracheobronchitis (croup). Use of intermittent positive-pressure breathing and racemic epinephrine. Am J Dis Child 1975; 129:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/35\">",
"      Corkey CW, Barker GA, Edmonds JF, et al. Radiographic tracheal diameter measurements in acute infectious croup: an objective scoring system. Crit Care Med 1981; 9:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/36\">",
"      Bjornson C, Russell KF, Vandermeer B, et al. Nebulized epinephrine for croup in children. Cochrane Database Syst Rev 2011; :CD006619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/37\">",
"      Kuusela AL, Vesikari T. A randomized double-blind, placebo-controlled trial of dexamethasone and racemic epinephrine in the treatment of croup. Acta Paediatr Scand 1988; 77:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/38\">",
"      Waisman Y, Klein BL, Boenning DA, et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). Pediatrics 1992; 89:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/39\">",
"      Butte MJ, Nguyen BX, Hutchison TJ, et al. Pediatric myocardial infarction after racemic epinephrine administration. Pediatrics 1999; 104:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/40\">",
"      Duncan PG. Efficacy of helium--oxygen mixtures in the management of severe viral and post-intubation croup. Can Anaesth Soc J 1979; 26:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/41\">",
"      Terregino CA, Nairn SJ, Chansky ME, Kass JE. The effect of heliox on croup: a pilot study. Acad Emerg Med 1998; 5:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/42\">",
"      Weber JE, Chudnofsky CR, Younger JG, et al. A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Pediatrics 2001; 107:E96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/43\">",
"      Vorwerk C, Coats T. Heliox for croup in children. Cochrane Database Syst Rev 2010; :CD006822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/44\">",
"      Skolnik NS. Treatment of croup. A critical review. Am J Dis Child 1989; 143:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/45\">",
"      Neto GM, Kentab O, Klassen TP, Osmond MH. A randomized controlled trial of mist in the acute treatment of moderate croup. Acad Emerg Med 2002; 9:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/46\">",
"      Scolnik D, Coates AL, Stephens D, et al. Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. JAMA 2006; 295:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/47\">",
"      Dulfano MJ, Adler K, Wooten O. Physical properties of sputum. IV. Effects of 100 per cent humidity and water mist. Am Rev Respir Dis 1973; 107:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/48\">",
"      Parks CR. Mist therapy: rationale and practice. J Pediatr 1970; 76:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/49\">",
"      Henry R. Moist air in the treatment of laryngotracheitis. Arch Dis Child 1983; 58:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/50\">",
"      Sasaki CT, Suzuki M. The respiratory mechanism of aerosol inhalation in the treatment of partial airway obstruction. Pediatrics 1977; 59:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31928/abstract/51\">",
"      Fanconi S, Burger R, Maurer H, et al. Transcutaneous carbon dioxide pressure for monitoring patients with severe croup. J Pediatr 1990; 117:701.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6008 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31928=[""].join("\n");
var outline_f31_11_31928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Budesonide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prednisolone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Betamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Repeated dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NEBULIZED EPINEPHRINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18926277\">",
"      Racemic versus&nbsp;L-epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OXYGEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MIST THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antitussives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Decongestants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sedatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/26/31144?source=related_link\">",
"      Approach to the management of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33480?source=related_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/63/32754?source=related_link\">",
"      Patient information: Croup (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/28/2500?source=related_link\">",
"      Patient information: Croup in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31929="TEG tracing interpretation";
var content_f31_11_31929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 635px\">",
"   <div class=\"ttl\">",
"    TEG tracing interpretation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 615px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    TEG: thromboelastograph",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Image of the TEG&reg; Thromboelastograph &reg; Hemostasis Analyzer Parameters LY30 Clot Breakdown is used by permission of Haemonetics Corporation.",
"     <br>",
"      Image of the TEG&reg; Thromboelastograph &reg; Hemostasis Analyzer Tracing is used by permission of Haemonetics Corporation.",
"      <br>",
"       TEG&reg; and Thromboelastograph &reg; are registers trademarks of Haemonetics Corporation in the US, other countries, or both.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31929=[""].join("\n");
var outline_f31_11_31929=null;
var title_f31_11_31930="Cerebrovascular complications of sickle cell disease";
var content_f31_11_31930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebrovascular complications of sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     ZoAnn Dreyer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/11/31930/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/11/31930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoocclusive phenomena and hemolysis are the clinical hallmarks of sickle cell disease (SCD). Vasoocclusion results in recurrent painful episodes (previously called sickle cell crisis) and a variety of serious organ system complications that can lead to life-long disabilities and even death.",
"   </p>",
"   <p>",
"    Hemoglobin S results from the substitution of a valine for glutamic acid as the sixth amino acid of the beta globin chain, which produces a hemoglobin tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/beta",
"    </span>",
"    S2) that is poorly soluble when deoxygenated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymerization of deoxy hemoglobin (Hb) S is essential to vasoocclusive phenomena [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymer assumes the form of an elongated rope-like fiber that usually aligns with other fibers, resulting in distortion into the classic crescent or sickle shape and a marked decrease in red cell deformability.",
"   </p>",
"   <p>",
"    However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play important roles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cerebrovascular complications associated with SCD (cerebral infarction, intracranial hemorrhage, and cognitive and behavioral changes) and potential strategies to prevent these complications are reviewed here (",
"    <a class=\"graphic graphic_figure graphicRef50288 \" href=\"mobipreview.htm?33/38/34408\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The other manifestations and overall treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cerebrovascular accident (CVA) is a leading cause of death in both children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/5\">",
"     5",
"    </a>",
"    ] and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/6\">",
"     6",
"    </a>",
"    ] with SCD. The reported age-adjusted incidence is 0.61 to 0.76 per 100 patient years (ie, 0.61 to 0.76 percent per year) during the first 20 years of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This rate is approximately 300 times higher than that seen in children without SCD (0.0023 per 100 patient years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of CVA varies with the genotype. In a series of 3647 patients from the Cooperative Study of Sickle Cell Disease, the age-adjusted incidence was 0.61 per 100 patients years in SCD (Hb SS); the respective values for Hb SC, Hb S-beta (+) thalassemia, and Hb S beta (0) thalassemia were substantially lower at 0.15, 0.09, and 0.08, respectively, per 100 patient years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. The likelihood of having a first CVA by age 20, 30, and 45 years was 11, 15, and 24 percent, respectively, for SCD compared with 2, 4, and 10 percent, respectively, for Hb SC (",
"    <a class=\"graphic graphic_figure graphicRef61397 \" href=\"mobipreview.htm?40/31/41469\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the precise definition of a CVA varies among authors, all agree that it includes any acute neurologic event secondary to arterial occlusion or hemorrhage that results in an ischemic event associated with neurologic signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms. Some authors also include transient ischemic events (TIA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ] and silent infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/11\">",
"     11",
"    </a>",
"    ] in the definition.",
"   </p>",
"   <p>",
"    Stroke is usually associated with narrowing or occlusion of the large cerebral arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/7,12,13\">",
"     7,12,13",
"    </a>",
"    ]. The type of stroke varies with age. An ischemic infarct is most common in children between the ages of 2 and 9, uncommon between the ages of 20 and 29, and has a second peak in adults over age 29 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. Hemorrhagic stroke can occur in children but is most frequent in individuals between the ages of 20 and 29. Overall data from the Cooperative Study of Sickle Cell Disease found that, among first CVAs in patients with SCD, 54 percent were caused by cerebral infarction, 11 percent by TIA, 34 percent by intracranial hemorrhage, and 1 percent had features of both infarction and hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the potentially devastating effect of stroke with its neurologic sequelae, subtle injury to the brain caused by sickle cell-related vascular compromise has become better understood with the availability of better imaging techniques (eg, magnetic resonance imaging [MRI], magnetic resonance angiography [MRA], and transcranial Doppler) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. These \"silent\" infarcts appear to play an important role in the development of cognitive deficits. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Cognitive and behavioral dysfunction and silent infarcts'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example of the magnitude of changes detected by MRI and MRA, the images of all 146 children with homozygous sickle cell anemia at a single institution were reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/15\">",
"     15",
"    </a>",
"    ]. At an average age of 10 years, the estimated prevalence of infarction, ischemic damage, or atrophy was 46 percent, while that for vasculopathy was 64 percent. Only 28 percent of children tested negative by both modalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CEREBRAL INFARCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725945\">",
"    <span class=\"h2\">",
"     Definition and pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral infarction is defined clinically by the presence of typical symptoms that last for at least 24 hours. Symptoms of infarctive stroke may include hemiparesis, dysphasia, gait disturbance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a change in level of consciousness. These findings are associated with a corresponding radiographic lesion. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Radiographic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although patients generally do not die acutely from infarctive stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ], substantial morbidity may occur. One report evaluated 11 children who developed a first cerebral infarct and presented with hemiparesis; 10 were hospitalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/16\">",
"     16",
"    </a>",
"    ]. At hospital discharge, two had major disability, five had mild-to-moderate disability, two had symptoms but no disability, and one was asymptomatic.",
"   </p>",
"   <p>",
"    Cerebral infarction is associated largely with occlusion or stenosis of the large intracranial arteries. The greater risk of infarction in younger children may be explained by the higher cerebral blood flow observed in this population. A number of other factors may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sludging and occlusion of small vessels by rigid red cells, which produces ischemia in the cerebral microcirculation",
"     </li>",
"     <li>",
"      Chronic anemia may reduce cerebrovascular reserve",
"     </li>",
"     <li>",
"      Flow-related hemodynamic injury to the arterial endothelium, which may promote adherence of sickle cells to the endothelium, producing further endothelial injury",
"     </li>",
"     <li>",
"      Development of moyamoya vessels (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Moyamoya syndrome'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      A hypercoagulable state",
"     </li>",
"     <li>",
"      HLA-related susceptibility for stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/19-23\">",
"       19-23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Silent cerebral ischemia is a related condition in which an infarct-like lesion is seen on MRI without a corresponding abnormality on neurologic exam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/24\">",
"     24",
"    </a>",
"    ]. Silent ischemia produces no overt sensorimotor deficits, but it is associated with poor cognitive performance and an increased risk for infarction in children with SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2725926\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents with SCD in the Cooperative Study of Sickle Cell Disease, the incidence per 100 patient years of a first cerebral infarct in a series from the United States was 0.70 between ages two and five years, 0.51 between ages six and nine years, 0.24 between 10 and 19 years of age, and then fell to 0.04 between the ages of 20 and 29 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. Attesting to the impact of this complication, it has been estimated that 11 and 24 percent of patients with sickle cell disease have a clinically apparent stroke by the ages of 20 and 45 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8,25\">",
"     8,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence is substantially lower in children with Hb SC, Hb S-beta (+) thalassemia, and Hb S-beta (0) thalassemia. Saudi Arabian children with SCD have less severe anemia and a much lower incidence of serious complications (6 to 25 percent of the rate of American or Jamaican black children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/26\">",
"     26",
"    </a>",
"    ]. High levels of Hb F were thought to account for the mild clinical course.",
"   </p>",
"   <p>",
"    Recurrent stroke occurs in approximately two-thirds of patients within two years of the initial event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/7,27-29\">",
"     7,27-29",
"    </a>",
"    ]. This risk is age-dependent: 6.4 per 100 patient years in patients with an initial CVA before age 20 compared with 1.6 per 100 patient years in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. Significant and long-lasting neurologic deficits are much more likely to occur after a second stroke.",
"   </p>",
"   <p>",
"    The incidence of silent ischemia appears to be greater than that of cerebral infarction and varies depending on the sensitivity of the imaging modality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one",
"      <span class=\"nowrap\">",
"       MRI/MRA",
"      </span>",
"      study of 65 neurologically intact children with SCD (age range: 1.3 to 5.9 years), 18 had silent infarcts (28 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/30\">",
"       30",
"      </a>",
"      ]. Factors associated with silent infarcts in these children included cerebral vessel stenosis on MRA, lower rates of vasoocclusive pain and acute chest syndrome, and lower hemoglobin levels.",
"     </li>",
"     <li>",
"      Another study looked for the presence of silent ischemic events in children with SCD enrolled in the Silent Cerebral Infarct Transfusion (SIT) trial, which evaluated the role of chronic red cell transfusion in preventing clinically silent infarctions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/24\">",
"       24",
"      </a>",
"      ]. Silent ischemic events, defined as an infarct-like lesion seen on MRI without corresponding abnormality on neurologic exam, were found in 8 of 220 children evaluated. In addition, acute silent events, defined as areas of restricted diffusion on diffusion-weighted MRI in the absence of corresponding focal neurologic findings, were found in 10 of 732 children. Repeat scans of two children showed a persistent silent lesion in one and resolution of the lesion in the other.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Cooperative Study of Sickle Cell Disease, the following major risk factors for completed infarctive stroke were identified on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior TIA: Relative risk [RR] 56",
"     </li>",
"     <li>",
"      Low steady state hemoglobin: RR 1.9 per 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease",
"     </li>",
"     <li>",
"      Rate of acute chest syndrome: RR 2.4 per event per year",
"     </li>",
"     <li>",
"      Episode of acute chest syndrome within the previous two weeks: RR 7.0",
"     </li>",
"     <li>",
"      Elevated systolic blood pressure: RR 1.3 per 10 mmHg increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a nested case-cohort study from the Dallas Newborn Cohort, lower steady-state pulse oximetry-derived oxygen saturation (SpO2) was associated with an increased risk of an overt stroke in children with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/31\">",
"     31",
"    </a>",
"    ], and correlated inversely with cerebral artery blood flow velocity as determined by transcranial Doppler ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The odds ratio for stroke was 1.32 (95% CI 1.15-1.51) for each unit (1 percent) decrease in SpO2 when the age of the patient was controlled. In patients with strokes, SpO2 fell even lower as the time to impending stroke decreased. Monitoring SpO2 can be used to identify children with hemoglobin desaturation who are at increased risk of stroke. In these patients, interventions to improve hemoglobin oxygen saturation and the underlying hemolytic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/33\">",
"     33",
"    </a>",
"    ] can be started that presumably will reduce the risk of stroke.",
"   </p>",
"   <p>",
"    Multilocus genotype screening and family studies have also been employed in an attempt to identify genetic polymorphisms or biologic differences that may increase or decrease the risk of stroke in patients with this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/20-22,34\">",
"     20-22,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predicting risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial Doppler (TCD), a noninvasive procedure, has become an important tool in predicting risk for stroke in patients with SCD. It measures the time-averaged mean velocity of blood flow in the large intracranial vessels, which is inversely related to arterial diameter (as documented by cerebral angiography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/35\">",
"     35",
"    </a>",
"    ]. A focal increase in velocity usually suggests arterial stenosis, whereas a bilateral increase may indicate bilateral arterial disease, increased blood flow, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624747\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, a mean transcranial Doppler (TCD) velocity &gt;170",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    is worrisome, and values &gt;200",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    in the middle cerebral or internal carotid artery are highly associated with an increased risk of stroke, even before lesions become evident on magnetic resonance angiograms (MRA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients with abnormal MRA findings and higher TCD velocities are at even higher risk for stroke.",
"   </p>",
"   <p>",
"    This association was illustrated in a study in which TCD was performed in 190 children with sickle cell disease (age at entry: 3 to 18 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/39\">",
"     39",
"    </a>",
"    ]. Twenty-three patients (12 percent) had an abnormal TCD (based upon the highest blood flow velocity in the middle cerebral artery), and seven developed a cerebral infarction after an average follow-up of 29 months. Six of the seven strokes occurred among the 23 patients with abnormal ultrasound results.",
"   </p>",
"   <p>",
"    A similar frequency of abnormal TCD findings (9.7 percent) was noted in the STOP I trial of children who had no prior history of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence fell with age, as does the incidence of cerebral infarction: 10.7, 9.4, and 6.3 percent between the ages of 2 to 8, 9 to 12, and 13 to 16, respectively. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention of a first stroke'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Significant risk factors for abnormally high cerebral velocities as determined by TCD in a cohort of 373 stroke-free children with SCD included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      G6PD deficiency",
"     </li>",
"     <li>",
"      Lower levels of hemoglobin",
"     </li>",
"     <li>",
"      Absence of alpha thalassemia",
"     </li>",
"     <li>",
"      Higher levels of serum lactate dehydrogenase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that G6PD deficiency and hemolysis independently increase the risk of cerebral vasculopathy in patients with SCD.",
"   </p>",
"   <p>",
"    Although TCD has been shown to be an effective screen to identify patients at high risk for stroke, many children with SCD in the United States are not screened because of lack of access to a center with TCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/41\">",
"     41",
"    </a>",
"    ]. One study from England developed an index based upon hemoglobin and aspartate transaminase levels and age, which correlated with the time-averaged mean of the maximum velocity detected by TCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/42\">",
"     42",
"    </a>",
"    ]. The authors suggest that this index could be used to identify patients who are more likely to have abnormal TCD and allow them to be prioritized for more urgent TCD.",
"   </p>",
"   <p>",
"    Another major obstacle to TCD screening has been the poor compliance of patients who must return to the medical center for the study on a day separate from their routine evaluations in SCD clinic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/43\">",
"     43",
"    </a>",
"    ]. However, in one study from St. Jude, where TCD screening is routinely available on the day of a clinic visit, 99 percent of patients at risk for stroke were able to be screened, and the incidence of first stroke was reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other techniques for assessing the risk of stroke in children with SCD have been proposed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small preliminary study suggested that conjunctival vessel velocity, as measured by a non-invasive computer-assisted intravital microscopy, correlated with abnormal intracranial vessel velocity, and may therefore be of use in identifying patients at high risk of stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study in four children with Hb SS disease suggested that a submandibular TCD approach may help identify obstruction in the proximal and mid portions of the internal carotid artery, improving its sensitivity as a screening tool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study of these approaches is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2726514\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar data on the value of TCD in predicting strokes in adults are lacking. In one study, the mean TCD velocity of adult patients with SCD was lower than that reported in children with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/47\">",
"     47",
"    </a>",
"    ]. In a subsequent report from the same institution, abnormalities were detected in 35 of 60 patients who underwent magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/48\">",
"     48",
"    </a>",
"    ]. In these patients, a time-averaged maximum mean velocity of 123.5",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    detected all the cases of middle or internal carotid artery intracranial stenosis with a specificity of 100 percent. Whether this translates to a lower threshold of TCD velocity to predict strokes in adults with SCD compared with that used in children with SCD (&gt;170",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention of a first stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of TCD to identify patients with SCD at high risk for stroke provided the rationale for the multi-institutional Stroke Prevention Trial in Sickle Cell Anemia (STOP I trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/16\">",
"     16",
"    </a>",
"    ]. A total of 130 children (mean age 8.3 years) with SCD or HbS-beta(0) thalassemia with no prior history of stroke were enrolled; all had a blood flow velocity above 200",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    on two repeated studies. The children were randomly assigned to observation or institution of a prophylactic chronic transfusion program with a goal HbS of less than 30 percent of total hemoglobin.",
"   </p>",
"   <p>",
"    The trial was prematurely terminated at a mean follow-up of 20 months because of a marked benefit in the prophylactic transfusion group: one infarction in the transfusion group compared with 10 infarctions and one intracerebral hemorrhage in the control group (",
"    <a class=\"graphic graphic_figure graphicRef57656 \" href=\"mobipreview.htm?4/40/4750\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thirty-seven percent of those enrolled in this trial had evidence of a prior silent infarct on the initial brain MRI. Transfusion therapy significantly reduced the risk of a new silent infarct or stroke in this group, while patients who were not provided transfusion therapy were at a higher risk of developing a new silent infarct or stroke during the study than those whose initial MRI was normal.",
"   </p>",
"   <p>",
"    In a subsequent follow-up report of 127 patients from the STOP I trial, six additional cases of stroke occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/49\">",
"     49",
"    </a>",
"    ]. Five of the six patients were in the trial arm of stopping blood transfusions. Stroke occurred in two patients in the immediate post-trial period prior to restarting transfusion therapy, in one patient who refused transfusion, and in two patients who had restarted transfusions. The one patient who had received blood transfusion and developed a stroke had discontinued transfusions at the end of the trial. All six patients had abnormal TCD velocities. Seventy-nine patients received transfusions during the post-trial follow-up. In the patients who did not have a stroke, patients who received transfusions were more likely to have normal TCD.",
"   </p>",
"   <p>",
"    Further suggestive evidence supporting the effectiveness of TCD screening and subsequent intervention in preventing stroke comes from calculation of stroke rates in California children with SCD before and after the 1998 publication of the results of the STOP I trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/10\">",
"     10",
"    </a>",
"    ]. Stroke rates were relatively constant between 1991 and 1998 at 0.88 events per 100 patient-years. In contrast, the observed rates were 0.50 and 0.17 per 100 patient years for 1999 and 2000, respectively (p &lt;0.005 for trend), suggesting more effective intervention following publication of the STOP I trial results.",
"   </p>",
"   <p>",
"    As an integral part of the STOP trial, TCD measurements were taken of flow velocity in the anterior cerebral artery (ACA) as well as the internal",
"    <span class=\"nowrap\">",
"     carotid/middle",
"    </span>",
"    cerebral arteries",
"    <span class=\"nowrap\">",
"     (ICA/MCA),",
"    </span>",
"    and the following findings were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among subjects at high risk of stroke due to high",
"      <span class=\"nowrap\">",
"       ICA/MCA",
"      </span>",
"      velocity (ie, &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec),",
"      </span>",
"      the risk of stroke more than doubled with elevated, compared with normal, ACA velocity (7.6 versus 3.2 per 100 patient-years).",
"     </li>",
"     <li>",
"      Among subjects with normal",
"      <span class=\"nowrap\">",
"       ICA/MCA",
"      </span>",
"      velocity (ie, &lt;170",
"      <span class=\"nowrap\">",
"       cm/sec),",
"      </span>",
"      the risk of stroke was more than 10-fold greater in those with elevated (ie, &ge;170",
"      <span class=\"nowrap\">",
"       cm/sec)",
"      </span>",
"      compared with normal ACA velocity (2.1 versus 0.20 per 100 patient-years).",
"     </li>",
"     <li>",
"      Although increased ACA flow in the absence of elevated flow in the",
"      <span class=\"nowrap\">",
"       ICA/MCA",
"      </span>",
"      was uncommon, when present it represented a stroke risk comparable to that seen in patients with conditionally abnormal",
"      <span class=\"nowrap\">",
"       ICA/MCA",
"      </span>",
"      flow (ie, 170 to 199",
"      <span class=\"nowrap\">",
"       cm/sec;",
"      </span>",
"      stroke risk 0.9 to 1.5 per 100 patient-years). The authors suggested that such findings should prompt early repeat studies to aid in decisions concerning interventions such as chronic transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the ability of TCD to identify children at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/39\">",
"     39",
"    </a>",
"    ] and of a prophylactic transfusion therapy protocol to provide benefit in such children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/16\">",
"     16",
"    </a>",
"    ], the use of TCD has become a routine screening tool in many centers that care for children with sickle cell anemia. The American Academy of Neurology published an assessment of TCD in May 2004, and concluded that TCD screening of children with sickle cell disease after age two is effective for assessing stroke risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the optimal frequency of TCD screening has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/51\">",
"     51",
"    </a>",
"    ]. Normal flow velocity on a single screening does not assure a continued \"low risk\" status. Accordingly, intermittent screening should be performed, especially in younger children and those with higher blood flow velocity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/52\">",
"     52",
"    </a>",
"    ]. An expert panel convened by the American Academy of Pediatrics recommends annual screening by TCD after age two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of repeat screening was shown in a retrospective study of 274 patients with sickle cell disease who had mean velocity values in the normal (ie, &lt;170",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    or \"conditional\" range (ie, 170 to 199",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/54\">",
"     54",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 153 subjects with normal flow velocity on initial examination, 25 (16 percent) converted to a \"conditional\" velocity on a subsequent examination and 4 (3 percent) converted directly to an abnormal flow velocity (ie, &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec)",
"      </span>",
"      over the ensuing 18 months.",
"     </li>",
"     <li>",
"      The 18-month cumulative incidence of conversion from \"conditional\" to abnormal flow velocity (ie, &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec)",
"      </span>",
"      was 23 percent, and was not influenced by age, initial mean velocity, blood pressure, oxygen saturation, or other laboratory values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We screen children with TCD study of the internal carotid artery and middle cerebral artery, and determine the timing of repeat screening based on the highest flow velocity in either artery, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flow velocity &lt;170",
"      <span class=\"nowrap\">",
"       cm/sec:",
"      </span>",
"      repeat annually",
"     </li>",
"     <li>",
"      Flow velocity &gt;170",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      and &le;200",
"      <span class=\"nowrap\">",
"       cm/sec:",
"      </span>",
"      repeat in three months",
"     </li>",
"     <li>",
"      Flow velocity &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec:",
"      </span>",
"      repeat in two to four weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with abnormal flow velocity of &ge;200",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    in the internal carotid artery or the middle cerebral artery on two repeated studies done by TCD are at high risk of stroke. Therefore, patients with two abnormal TCD studies within a two- to four-week period should be entered into a stroke prevention protocol consisting of chronic transfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/53\">",
"     53",
"    </a>",
"    ]. This recommendation is supported by numerous studies and randomized clinical trials demonstrating that chronic transfusion therapy is effective primary prophylaxis for stroke in patients with SCD, and is the treatment of choice for high-risk patients. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Chronic transfusion therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Chronic transfusion therapy poses certain risks, including alloimmunization and iron overload; and although TCD has a high sensitivity for predicting stroke, the specificity is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/25\">",
"     25",
"    </a>",
"    ]. For families who refuse transfusion therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    has been suggested as a second-line option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/55\">",
"     55",
"    </a>",
"    ]. Although studies have shown that hydroxyurea may lower TCD velocities, minimal information is available about its efficacy for primary or secondary prevention of stroke in SCD, and there are no randomized trials to support the efficacy of hydroxyurea over chronic transfusion therapy. Moreover, preliminary results from a randomized trial suggest that chronic transfusion therapy is more effective than hydroxyurea to prevent recurrent stroke. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Hydroxyurea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children entering a stroke prevention protocol should be carefully screened for neurologic abnormalities as well as language and learning deficits. In cases with neurologic findings or dramatic differences in TCD readings, magnetic resonance",
"    <span class=\"nowrap\">",
"     imaging/magnetic",
"    </span>",
"    resonance angiography",
"    <span class=\"nowrap\">",
"     (MRI/MRA)",
"    </span>",
"    exams may be appropriate for diagnosing silent infarction or other abnormalities. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Radiographic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Stopping transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a prophylactic transfusion program can be stopped in patients without a prior stroke was addressed in the STOP II trial, which studied the effect of stopping transfusion in children thought to be at lower risk for stroke because of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment with periodic transfusions for a minimum of 30 months with a HbS level &lt;30 percent in at least 20 of the 30 months",
"     </li>",
"     <li>",
"      Reversion of TCD velocities to normal (ie, two normal TCD examinations at least two weeks apart while receiving transfusions)",
"     </li>",
"     <li>",
"      No prior stroke and no moderate-to-severe arterial lesions on magnetic resonance angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The study was prematurely terminated by the NHLBI at which time 14 of the 41 patients randomly assigned to stop transfusions reverted to a high risk of stroke as measured by TCD, and two other patients had stroke recurrence. These 16 events occurred within a median time of 3.2 months (range: 2 to 10 months) following randomization. There were no strokes or reversion to high stroke risk in the 38 subjects assigned to continue transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent follow-up of the 79 participants in the STOP II trial evaluated the effect of stopping transfusions on the development or progression of silent brain infarcts as detected by magnetic resonance imaging. Results included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the 21 subjects with silent brain infarcts at study entry, new lesions were seen in 3 of the 10 subjects in whom transfusions were continued and in 5 of the 11 in whom transfusions were stopped.",
"     </li>",
"     <li>",
"      For the 58 subjects with a normal MRI at study entry, new lesions were seen in none of the 28 in whom transfusions were continued, and in 6 of the 30 in whom transfusions were stopped.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One interpretation of the STOP II trial is that children with sickle cell disease identified as being at high risk for stroke will likely be receiving extended, if not life-long, RBC transfusions for prevention of stroke as well as prevention of silent brain infarcts. As such they will resemble children with beta-thalassemia major who also require regular RBC transfusion support and face the clinical consequences of iron overload. It is likely that these children will either require iron chelation or earlier consideration for allogeneic hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NHLBI has issued a clinical alert recommending that blood transfusions be continued in such patients. They further concluded that the choice of clinical management, including whether to continue periodic transfusions or to stop transfusions with TCD monitoring every two to three months, must be made on a case-by-case basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of importance, in the 209 patients who underwent randomization in the STOP I and STOP II trials, there were 20 strokes. The last TCD examination before the stroke showed abnormal velocities in all cases, confirming that abnormal TCD velocities are a good indicator of the risk of stroke both before transfusion is initiated as well as after it is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prevention of recurrent stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, patients with SCD who have an initial stroke have a high risk of recurrent stroke. Recurrent stroke occurs in approximately two-thirds of patients within two years of the initial event, and the risk is particularly high in patients under age 20. Significant and long-lasting neurologic deficits are much more likely to occur after a second stroke. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Cerebral infarction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because of these high recurrence risks, we recommend intervention to reduce the risk of recurrence in any patient with SCD who has had a stroke. For management of an acute stroke event, exchange transfusion is the preferred initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/59\">",
"     59",
"    </a>",
"    ]. For ongoing prevention, chronic transfusion protocols are typically used. Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and hematopoietic cell transplantation also has been considered. Although hydroxyurea has been considered as an alternative to chronic transfusion therapy, the SWiTCH Trial demonstrated a higher incidence of recurrent stroke in those receiving hydroxyurea than in those receiving chronic transfusion. Based on this recently released safety data, hydroxyurea can no longer be considered adequate as the sole therapy for prevention of recurrent stroke. (See",
"    <a class=\"local\" href=\"#H13160961\">",
"     'SWiTCH trial'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend urgent transfusion therapy for patients with SCD who present with stroke. Ideally, this is accomplished by an immediate exchange transfusion to achieve a goal HbS fraction of &lt;30 percent and a hemoglobin level of approximately, but not greater than, 10",
"    <span class=\"nowrap\">",
"     gm/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Although the initial optimal acute therapy following a stroke in children with sickle cell disease remains uncertain, exchange transfusion appears to be more effective than simple transfusion in preventing second strokes. This was illustrated in a retrospective study of 137 children with sickle cell disease and a history of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/59\">",
"     59",
"    </a>",
"    ]. Treatment information was available in 52 patients who presented within 24 hours of onset of initial stroke symptom (ie, weakness, paresis, seizures,",
"    <span class=\"nowrap\">",
"     dysarthria/aphasia).",
"    </span>",
"    Second strokes were more likely in patients who received simple transfusions (8 of 14 patients) compared with those who were treated with exchange transfusions (8 of 38 patients), (RR 5.0, 95% CI 1.3-18.6). There was no difference between the two treated groups in the frequency of risk factors. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Chronic transfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute episode, patients should be treated with chronic transfusion therapy. Patients who have been stabilized with chronic transfusion therapy should be evaluated for the option of hematopoietic stem cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic transfusion can reduce the incidence of recurrent stroke to below 10 percent when routine monthly red blood cell transfusions are given to maintain the hemoglobin S fraction at less than 30 percent of total hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/28,29,53,60-63\">",
"     28,29,53,60-63",
"    </a>",
"    ]. Results of three studies evaluating the efficacy of this approach are reported below.",
"   </p>",
"   <p>",
"    In one series of 60 patients followed for a mean of approximately three years, eight (13 percent) had a recurrent stroke and 13 had at least one transient ischemic attack [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/62\">",
"     62",
"    </a>",
"    ]. The HbS fraction was higher than the desired maximum of 30 percent in almost all of the recurrent strokes and one-half of the transient ischemic attacks. The results of one retrospective study suggest that the presence of moyamoya vessels on angiography defines a subpopulation at increased risk of recurrent stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Moyamoya syndrome'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective cohort study enrolled 40 children with sickle cell disease and overt stroke who were receiving regularly scheduled blood transfusion therapy and were followed by magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) of the brain every one to two years. Results of this study included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive cerebral infarcts occurred in 18 (45 percent), seven with a second overt stroke and 11 with new silent cerebral infarcts. In four of the seven children with a second overt stroke, HbS levels were &lt;30 percent at the time of the second event (10, 17, 21, and 28 percent), while HbS levels were 38 and 48 percent in two and not measured in the third. Of the seven children with a second overt stroke, three subsequently had a third stroke and one had a fourth stroke.",
"     </li>",
"     <li>",
"      Cerebral vasculopathy was identified on the first MRA in 63 percent of the subjects. Cerebral vasculopathy worsened in 38 percent of the subjects during the study, including five children who had no cerebral vasculopathy identified on their initial MRA.",
"     </li>",
"     <li>",
"      A strong association between worsening cerebral vasculopathy by MRA and progressive infarcts on MRI was found (RR 12.7; 95% CI 2.6-60).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third program, the Creteil newborn SCA cohort, systematically assessed 217 children with sickle cell disease by TCD starting at 12 to 18 months of age, performed",
"    <span class=\"nowrap\">",
"     MRI/MRA",
"    </span>",
"    every two years (or earlier for those with abnormal TCD), and offered a transfusion program, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , or hematopoietic cell transplantation for selected individuals. At a median follow-up time of 6.2 years, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cumulative risks at 14 to 18 years of age were 1.9, 29.6, 22.6, and 37.1 percent for overt stroke, abnormal TCD, stenosis, and silent stroke, respectively.",
"     </li>",
"     <li>",
"      The cumulative cerebral risk for all of these events (overt stroke, abnormal TCD, stenoses, silent strokes) was 49.9 percent (95% CI 40-59 percent) by age 14.",
"     </li>",
"     <li>",
"      Independent predictors for cerebral risk included baseline reticulocyte count and lactate dehydrogenase level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results of these three studies indicate that children with sickle cell disease, even if enrolled in diagnostic and therapeutic programs early after birth, experience silent infarcts and worsening cerebral vasculopathy at a high rate, and indicate that current treatment programs (eg, maintaining HbS at &lt;30 percent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ) are less effective than previously thought. The French investigators noted the positive development of a reduced risk for overt stroke (1.9 percent, down from a historical high of 11 percent) but also documented an overall incidence of cerebral events of 50 percent even when they started their program within 1.5 years of birth. The two latter reports raise questions regarding the traditional objective of targeting HbS levels to less than 30 percent and indicate the need for further studies.",
"   </p>",
"   <p>",
"    Given the apparent need for prolonged transfusion therapy, efforts have been made to modify the transfusion regimen in an attempt to minimize transfusion-associated complications such as iron overload, alloimmunization, and infection. In one study, 15 patients who had been free of stroke or neurologic deterioration for four years and had received chronic transfusions to maintain a hemoglobin S fraction &lt;30 percent were placed on a modified regimen in which the acceptable goal hemoglobin S fraction was raised to &lt;50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/67\">",
"     67",
"    </a>",
"    ]. At a median follow-up of 84 months, no recurrent cerebrovascular events occurred and simple blood transfusion requirements fell by 17 to 48 percent (mean 31 percent).",
"   </p>",
"   <p>",
"    Whether chronic transfusion therapy can be safely stopped in a patient with a prior stroke remains unclear. However, information is now available that suggests that for patients receiving transfusion therapy for primary prevention there is not a clear point at which transfusion therapy can safely be withdrawn. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Prevention of a first stroke'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Attempts to discontinue this regimen at one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/60\">",
"     60",
"    </a>",
"    ] or as late as 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/68\">",
"     68",
"    </a>",
"    ] following the initial stroke event have resulted in a high rate of stroke recurrence. In one report of 10 patients who received transfusion therapy for a mean of 9.5 years after an initial stroke, five had a recurrent ischemic event within one year after the cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13944399\">",
"    <span class=\"h4\">",
"     Program costs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigators from Jackson Children&rsquo;s Hospital and the University of Miami Division of Pediatric Hematology Oncology performed a retrospective analysis between January 1997 and April 1998 of the cost of chronic transfusion for stroke prevention in sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/69\">",
"     69",
"    </a>",
"    ]. Sixteen patients had experienced a previous stroke and five were enrolled in the Stroke Prevention Trial (STOP) in sickle cell disease. Charges ranged from $9828 to $50,852 per patient per year. Outpatient charges, chelation charges, and physician-related charges accounted for 53, 42, and 5 percent of the total charges. Charges for patients who required chelation therapy ranged from $31,143 to $50,852 per patient per year. Desferoxamine accounted for 71 percent of the chelation-related charges, which ranged from $12,719 to $24,845 per patient per year. The authors concluded that these data should be considered in reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as allogeneic stem cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risks associated with even modified chronic red cell transfusion therapy, alternatives to transfusion have been sought [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/25\">",
"     25",
"    </a>",
"    ]. One possibility is pharmacologic manipulation of fetal hemoglobin (HbF) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"     \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach was evaluated in 35 children with SCD and stroke in whom transfusion therapy was discontinued because of the presence of alloantibodies or autoantibodies, recurrent stroke on transfusion therapy, iron overload, noncompliance,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    allergy, parental request, or religious objection to blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/71\">",
"     71",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    was begun at a dose of 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and then increased to 30 to 35",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day based upon hematologic toxicity. In 20 patients, transfusion therapy was continued until the full-dose of hydroxyurea was tolerated; in the remaining 15 there was no overlap between therapies. The overall rate of recurrent stroke per 100-patient years was 5.7; however, the rate in the group of patients with overlapping transfusion and hydroxyurea therapy was 3.6, which compares favorably to the rate in patients receiving chronic transfusion therapy (2.2 to 4.2 per 100-patient years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/62,75\">",
"     62,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second study, 59 children with sickle cell anemia treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    for routine clinical management underwent serial TCD evaluation; 37 children with increased flow velocities were then enrolled in a prospective phase II trial, with TCD velocities tested at the maximal tolerated dose (MTD) of hydroxyurea and one year later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/72\">",
"     72",
"    </a>",
"    ]. When the MTD was reached, there was a significant decrease in the maximal TCD flow velocities for both the middle and anterior cerebral arteries. One year after reaching MTD, the TCD velocity was only minimally lower. The overall incidence of new neurologic events for the entire cohort during treatment was 0.5 events per 100 patient-years of observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13160961\">",
"    <span class=\"h4\">",
"     SWiTCH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the two above studies, a large multicenter trial was launched (Stroke With Transfusions Changing to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    , or",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT00122980?term=switch&amp;rank=2\">",
"     SWiTCH trial",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/76\">",
"     76",
"    </a>",
"    ]. The trial enrolled children and adolescents with SCD who had experienced a stroke and had received at least 18 months of transfusion therapy along with evidence of iron overload, which was often extreme (eg, median hepatic iron levels of 13",
"    <span class=\"nowrap\">",
"     mg/gram",
"    </span>",
"    dry weight and median serum ferritin levels of 3164",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was a noninferiority phase III trial, comparing standard therapy",
"    <span class=\"nowrap\">",
"     (transfusion/chelation)",
"    </span>",
"    with experimental therapy",
"    <span class=\"nowrap\">",
"     (",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"      hydroxyurea",
"     </a>",
"     /phlebotomy),",
"    </span>",
"    with the primary composite endpoint allowing for an increased stroke risk with",
"    <span class=\"nowrap\">",
"     hydroxyurea/phlebotomy",
"    </span>",
"    (ie, estimated stroke risks of 6 and 12 percent for the standard and experimental arms, respectively) but requiring superiority of the experimental arm for reducing hepatic iron concentration.",
"   </p>",
"   <p>",
"    In the SWiTCH trial, subjects were randomly assigned to either continue transfusion therapy or to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    treatment. To treat the underlying iron overload, subjects receiving transfusion therapy were given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    , and those switching to hydroxyurea received serial phlebotomy to remove the excess iron. The SWiTCH trial was terminated at the first scheduled interim analysis for futility to reach the primary end point, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stroke risk",
"      </strong>",
"      ��� There were no strokes in the 66 subjects randomly assigned to treatment with transfusion and iron chelation, while there were seven strokes (10 percent) in the 67 subjects randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      plus phlebotomy. This was within the noninferiority stroke risk margin for the study.",
"     </li>",
"     <li>",
"      <strong>",
"       Removal of iron",
"      </strong>",
"      ��� Liver iron content was not significantly different between the two study arms (16.6 versus 15.7",
"      <span class=\"nowrap\">",
"       mg/g",
"      </span>",
"      dry weight for the standard and experimental arms, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was therefore concluded that transfusions plus iron chelation remain a preferable way to manage children with sickle cell anemia, stroke, and iron overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTRACRANIAL HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial hemorrhage (ICH), also called hemorrhagic stroke in this setting, accounts for approximately one-third of cerebrovascular events in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. The site of bleeding may be subarachnoid, intraparenchymal, intraventricular, or a combination of these locations. The peak incidence of ICH is between the ages of 20 and 29 in comparison to cerebral infarction, which is much more common in children. Approximately 3 percent of children with SCD will have a hemorrhagic stroke by 20 years of age, and 25 to 50 percent will die within two weeks of the event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Cooperative Study of Sickle Cell Disease, two major risk factors for hemorrhagic stroke were identified on multivariate analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low steady state hemoglobin &ndash; RR 1.6 per 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease",
"     </li>",
"     <li>",
"      Increased steady state leukocyte count &ndash; RR 1.9 per",
"      <span class=\"nowrap\">",
"       5000/microL",
"      </span>",
"      increase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a small retrospective case-cohort study from two children hospitals in the United States suggested that a recent history of hypertension, transfusions, or corticosteroid therapy was more likely in children with sickle cell disease who experienced hemorrhagic stroke compared to those with ischemic strokes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical manifestations and evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms associated with ICH are frequently different from those seen with infarction, which typically produces focal deficits, such as hemiparesis, and are dependent upon the location of the hemorrhage. The most common presenting features of ICH include severe headache, vomiting, stiff neck, and alterations in consciousness. Coma and seizures in the absence of hemiparesis strongly suggest ICH.",
"   </p>",
"   <p>",
"    Angiography should be considered in all patients with ICH to identify the cause of bleeding and to guide further therapy. Aneurysms should be repaired surgically when possible. When large vessel vasculopathy is present without aneurysm or vascular malformation, chronic transfusion may be recommended. However, in patients for whom the cause of hemorrhage remains unclear, chronic transfusion will not be helpful and is not indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Radiographic imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mortality rate in patients with ICH is as high as 24 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8,80-82\">",
"     8,80-82",
"    </a>",
"    ]. Deaths generally occur within the first two weeks of the event, many on the first day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, some survivors are left with moderate to severe residual disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Subarachnoid hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of ICH represent subarachnoid hemorrhage resulting from the rupture of one or more aneurysms; multiple aneurysms are present in approximately 45 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Injury to the endothelium and the high flow conditions in sickle cell disease are thought to promote the formation of these aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/80,83\">",
"     80,83",
"    </a>",
"    ]. The time required for these changes to occur may account for the peak incidence in young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of subarachnoid hemorrhage in children with SCD consists of nonaggressive hydration and, as in other patients with this disorder,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    to minimize the incidence of vasospasm, surgery (eg, clip ligation), and treatment of vasospasm should it occur after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Blood pressure management may present a dilemma if hypertension occurs; lowering the pressure may reduce bleeding but also may result in ischemia or infarction because a higher pressure may be required to maintain cerebral perfusion because of the typical increase in intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Intraventricular hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular hemorrhage (IVH) may be associated with rupture of anterior cerebral artery aneurysms or direct extension of intraparenchymal hemorrhage into the lateral or third ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/86\">",
"     86",
"    </a>",
"    ]. In addition, patients who have experienced previous cerebral infarction are at risk for intraventricular and intraparenchymal hemorrhage as a late event, months to years after the ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemorrhage into the third ventricle or cerebral aqueduct places patients at high risk for late deterioration. Such patients may be awake and alert immediately following such a bleed and then become comatose over the ensuing 48 hours because of obstructive hydrocephalus and ventricular dilation. Emergent ventricular drainage may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Moyamoya syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 30 percent of patients with SCD who develop intracranial hemorrhage, a moyamoya syndrome (sometimes termed \"pseudo-moyamoya\" or secondary moyamoya pattern) in the basal arteries may be demonstrated by angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/84,87\">",
"     84,87",
"    </a>",
"    ]. These abnormalities may be the source of hemorrhage. This pattern is named for its resemblance to findings in Moyamoya disease, a chronic cerebrovascular disease of uncertain etiology that occurs primarily in Japan and other Asian countries and is characterized by severe bilateral stenosis or occlusion of the arteries around the circle of Willis, with prominent collateral circulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=see_link\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Patients with SCD who develop moyamoya syndrome appear to be at risk for recurrence of strokes. This was illustrated in a retrospective study of 44 patients maintained on chronic transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/64\">",
"     64",
"    </a>",
"    ]. Nineteen of the 44 patients had evidence of moyamoya collateral circulation based upon either magnetic resonance or conventional angiography. The risk of recurrent stroke was greater in patients with moyamoya disease (11 of 19 patients, 58 percent) than those without moyamoya disease (7 of 25 patients, 28 percent).",
"   </p>",
"   <p>",
"    In children with SCD and moyamoya syndrome, surgical treatment has been used in an effort to restore the circulation of the ischemic brain area, thereby reducing the risk of ischemic stroke. In one report, indirect revascularization using encephaloduroarteriosynangiosis (EDAS) was performed in 12 patients with SSD and documented moyamoya syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/88\">",
"     88",
"    </a>",
"    ]. Ten patients had a history of stroke including four who were compliant with a transfusion protocol at the time of their stroke. At a median follow up of 47 months after the procedure, seven patients had postsurgical angiography, which showed revascularization of the affected area in all cases. Two of the 12 patients experienced strokes.",
"   </p>",
"   <p>",
"    Although there are no randomized, controlled trials determining the effectiveness of surgical treatment in patients with SCD and moyamoya disease, these results suggest that EDAS performed by experienced neurosurgeons is a reasonable option for these patients given their poor outcome without intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7751?source=see_link&amp;anchor=H4#H4\">",
"     \"Moyamoya disease: Prognosis and treatment\", section on 'Secondary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to intracranial hemorrhage, rare case reports of epidural hematoma developing in patients with SCD have been reported. In these cases, the hematomas were associated with bony infarcts of the skull and required aggressive surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic (CT) scanning and magnetic resonance imaging (MRI) have become the accepted methods for confirming a clinical diagnosis of cerebral infarction or intracranial hemorrhage in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/90-94\">",
"     90-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An unenhanced CT scan generally is the easiest study to obtain soon after an acute neurologic event. It will localize an area of hemorrhage immediately, but may not become abnormal for up to six hours after an infarct.",
"     </li>",
"     <li>",
"      Compared with CT, MRI offers improved resolution and the ability to demonstrate areas of abnormality within two to four hours following an infarct. One limitation is that MRI requires cooperation of the patient for a prolonged period; it is also considerably more expensive than CT.",
"     </li>",
"     <li>",
"      As noted above, transcranial Doppler can be used to identify patients at risk for stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/35-37,39\">",
"       35-37,39",
"      </a>",
"      ]. It has variable sensitivity for the detection of flow abnormalities due to prior infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/11,95\">",
"       11,95",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Predicting risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance angiography (MRA) can identify vascular disease with accuracy similar to that of angiography and MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/11,93,95-97\">",
"       11,93,95-97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Positron emission tomography (PET) can be used to gauge the functional activity of the cerebral tissues and, therefore, microvascular blood flow. PET scanning in conjunction with MRI may identify a greater number of patients with silent infarcts than does MRI alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COGNITIVE AND BEHAVIORAL DYSFUNCTION AND SILENT INFARCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although numerous studies have been performed, drawing conclusions from cognitive and behavioral evaluations of children with SCD has been difficult. Among the major limitations are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/99\">",
"     99",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many reports did sibling controls and were, therefore, unable to control for socioeconomic, parental, and ethnic variables.",
"     </li>",
"     <li>",
"      Studies performed prior to the availability of MRI could not identify children with silent infarcts. Thus, deficits in general intelligence; in academic skills such as reading, writing, and spelling; and in neuropsychologic functions such as attention, visuospatial ability, and memory were ascribed to SCD itself in children who had no history of an overt stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/100-103\">",
"       100-103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Results have been considerably diverse among studies of behavioral and psychologic function because of the use of highly variable assessment measures and inconsistencies in defining the control group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI has enhanced our understanding of the pathogenesis of these deficits. Although cerebral infarction in children with SCD is usually symptomatic, 10 to 30 percent have \"silent\" infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/30,90,91,104-106\">",
"     30,90,91,104-106",
"    </a>",
"    ]; they are less common in Hb SC disease, occurring in 3 percent of patients in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/90\">",
"     90",
"    </a>",
"    ]. Silent infarcts are defined by the presence of T-2 weighted signal changes on MRI consistent with infarction in patients with a normal neurologic examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/107-109\">",
"     107-109",
"    </a>",
"    ]. They are more common in patients with a history of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/105,110,111\">",
"     105,110,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of silent infarcts on cognitive and behavioral function can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from the Cooperative Study of Sickle Cell Disease evaluated 135 children with MRI and neuropsychologic evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/104\">",
"       104",
"      </a>",
"      ]. On most measures of neuropsychologic evaluation, children with a history of CVA performed significantly worse than did children with silent infarcts or no MRI abnormality. On tests of arithmetic, vocabulary, and visual motor speed and coordination, children with silent infarcts performed significantly worse than children with no MRI abnormality. Similar findings were noted in a smaller series in which children with a silent infarct had impaired neuropsychologic performance relative to sibling controls or patients without a stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/112\">",
"       112",
"      </a>",
"      ]. The location of the infarct is the primary determinant of neuropsychologic impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/112-115\">",
"       112-115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of children without a silent infarct on MRI have revealed cognitive functioning similar to siblings without SCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/112\">",
"       112",
"      </a>",
"      ]. However, measurement of cerebral blood flow by continuous arterial spin-labeling MRI may identify children with neurocognitive impairment before damage is evident by structural MRI or TCD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/116\">",
"       116",
"      </a>",
"      ]. This technique is not available in many medical centers, and the reproducibility of these findings needs to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that, in the absence of cerebral disease as determined by symptoms or MRI, no differences in cognitive ability are attributable solely to SCD. However, one study found that behavioral and psychologic functioning in children with SCD was essentially the same as that in other children with chronic illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/117\">",
"     117",
"    </a>",
"    ]. Although the risk is somewhat increased, only a few children develop frank psychiatric disorders or meet diagnostic criteria for a depressive disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further understand the role of silent infarction on neurocognitive outcomes and on potential evolution to symptomatic stroke, and to answer the question as to what is the best therapy, the National Institutes of Health is sponsoring a large multicenter randomized trial (Silent Infarct Transfusion Study) in children between 6 and 12 years of age. Following screening and with detection of silent stroke, patients will be randomly assigned to transfusion therapy or observation for a three-year period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/107,119\">",
"     107,119",
"    </a>",
"    ]. Analysis of study candidates at baseline identified low hemoglobin concentration, high systolic blood pressure, and male gender as predictors of silent cerebral infarct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/108\">",
"     108",
"    </a>",
"    ]. There is presently no high level evidence to support the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    or hematopoietic cell transplantation for individuals with sickle cell disease and silent cerebral infarcts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/11/31930/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192012851\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebrovascular accident (CVA, stroke) is a leading cause of death in children and adults with sickle cell disease (SCD). The risk of CVA varies by genotype (",
"      <a class=\"graphic graphic_figure graphicRef61397 \" href=\"mobipreview.htm?40/31/41469\">",
"       figure 2",
"      </a>",
"      ). The risk of having a CVA by age 20 is approximately 11 percent for patients with SCD; this incidence is more than 300 times higher than that seen in children without SCD. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of infarctive stroke may include hemiparesis, dysphasia, gait disturbance,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a change in level of consciousness. Although patients generally do not die acutely from infarctive stroke, substantial morbidity may occur. Recurrent stroke occurs in approximately two-thirds of patients within two years of the initial event, and is most common in children and adolescents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Cerebral infarction'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Transcranial Doppler (TCD) is an important tool in predicting risk for stroke in patients with SCD, and can detect arterial stenosis at an earlier stage of disease than magnetic resonance angiography (MRA). It measures the time-averaged mean velocity of blood flow in the large intracranial vessels, and a focal area of higher velocity usually indicates arterial stenosis. In children, a mean velocity &gt;200",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      in the middle cerebral or internal carotid artery are highly associated with an increased risk of stroke, even before lesions become evident on magnetic resonance angiograms (MRA). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Predicting risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with SCD should be routinely screened with TCD to assess risk for stroke. This is especially valuable in young children. In our practice, we screen patients annually after age two. If the TCD velocity is between 170 and 200",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      in the internal carotid or middle cerebral artery, we re-screen in three months; if the TCD is &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec,",
"      </span>",
"      we rescreen in two to four weeks. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all children with a mean velocity &ge;200",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      on two TCD studies within a two to four-week period be treated with a stroke prevention protocol utilizing prophylactic transfusion, rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Once a patient has entered a prophylactic transfusion program, it should usually be continued indefinitely unless other preventive measures are taken, because the risk of stroke returns if transfusions are stopped. Complications of chronic transfusion therapy include iron overload and alloimmunization. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Recommendation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic transfusion therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Stopping transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of high recurrence risks, we recommend intervention to reduce the risk of recurrence in any patient with SCD who has had a stroke. For initial treatment, exchange transfusion is typically used with a goal of achieving a HbS fraction of &lt;30 percent and a hemoglobin level of approximately but no greater than 10",
"      <span class=\"nowrap\">",
"       gm/dL.",
"      </span>",
"      After the acute episode, we recommend chronic transfusion therapy rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic transfusion therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those with iron overload as the result of chronic transfusion therapy, we recommend continuation of chronic transfusion along with iron chelation rather than treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      plus phlebotomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13160961\">",
"       'SWiTCH trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intracranial hemorrhage (ICH), also called hemorrhagic stroke in this setting, accounts for approximately one-third of cerebrovascular events in patients with SCD. It is most common among young adults and has a high mortality rate. Presenting features of ICH include severe headache, vomiting, stiff neck, and alterations in consciousness. Coma and seizures in the absence of hemiparesis strongly suggest ICH. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Intracranial hemorrhage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical manifestations and evaluation'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The majority of cases of ICH represent subarachnoid hemorrhage resulting from the rupture of one or more aneurysms. Treatment of subarachnoid hemorrhage in children with SCD consists of nonaggressive hydration and, as in other patients with this disorder,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/20/16710?source=see_link\">",
"       nimodipine",
"      </a>",
"      to minimize the incidence of vasospasm, surgery (eg, clip ligation) if aneurisms are identified by angiography, and treatment of vasospasm should it occur after surgery. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Subarachnoid hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraventricular hemorrhage (IVH) may be associated with rupture of anterior cerebral artery aneurysms or direct extension of intraparenchymal hemorrhage into the lateral or third ventricle. IVH may cause obstructive hydrocephalus and ventricular dilation, which may present with sudden neurologic deterioration two or more days after an initial hemorrhagic event. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Intraventricular hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/1\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/2\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/3\">",
"      Hoppe C. Defining stroke risk in children with sickle cell anaemia. Br J Haematol 2005; 128:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/4\">",
"      Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol 2012; 157:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/5\">",
"      Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989; 84:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/6\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/7\">",
"      Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med 1978; 65:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/8\">",
"      Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/9\">",
"      Fullerton HJ, Wu YW, Zhao S, Johnston SC. Risk of stroke in children: ethnic and gender disparities. Neurology 2003; 61:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/10\">",
"      Fullerton HJ, Adams RJ, Zhao S, Johnston SC. Declining stroke rates in Californian children with sickle cell disease. Blood 2004; 104:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/11\">",
"      DeBaun MR, Glauser TA, Siegel M, et al. Noninvasive central nervous system imaging in sickle cell anemia. A preliminary study comparing transcranial Doppler with magnetic resonance angiography. J Pediatr Hematol Oncol 1995; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/12\">",
"      Sarnaik SA, Lusher JM. Neurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol 1982; 4:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/13\">",
"      Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972; 287:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/14\">",
"      Steen RG, Emudianughe T, Hankins GM, et al. Brain imaging findings in pediatric patients with sickle cell disease. Radiology 2003; 228:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/15\">",
"      Steen RG, Xiong X, Langston JW, Helton KJ. Brain injury in children with sickle cell disease: prevalence and etiology. Ann Neurol 2003; 54:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/16\">",
"      Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339:5.",
"     </a>",
"    </li>",
"    <li>",
"     Adams RJ. Neurologic complications. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Robert P, Hebbel RP, et al (Eds), Raven Press, Ltd, New York 1994. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/18\">",
"      Powars DR. Management of cerebral vasculopathy in children with sickle cell anaemia. Br J Haematol 2000; 108:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/19\">",
"      Styles LA, Hoppe C, Klitz W, et al. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 2000; 95:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/20\">",
"      Hoppe C, Cheng S, Grow M, et al. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. Br J Haematol 2001; 114:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/21\">",
"      Driscoll MC, Hurlet A, Styles L, et al. Stroke risk in siblings with sickle cell anemia. Blood 2003; 101:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/22\">",
"      Hoppe C, Klitz W, Noble J, et al. Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 2003; 101:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/23\">",
"      Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 2004; 103:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/24\">",
"      Quinn CT, McKinstry RC, Dowling MM, et al. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol 2013; 70:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/25\">",
"      Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood 2009; 114:5117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/26\">",
"      Perrine RP, Pembrey ME, John P, et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med 1978; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/27\">",
"      Balkaran B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/28\">",
"      Russell MO, Goldberg HI, Hodson A, et al. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984; 63:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/29\">",
"      Sarnaik S, Soorya D, Kim J, et al. Periodic transfusions for sickle cell anemia and CNS infarction. Am J Dis Child 1979; 133:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/30\">",
"      Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009; 146:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/31\">",
"      Quinn CT, Sargent JW. Daytime steady-state haemoglobin desaturation is a risk factor for overt stroke in children with sickle cell anaemia. Br J Haematol 2008; 140:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/32\">",
"      Quinn CT, Variste J, Dowling MM. Haemoglobin oxygen saturation is a determinant of cerebral artery blood flow velocity in children with sickle cell anaemia. Br J Haematol 2009; 145:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/33\">",
"      O'Driscoll S, Height SE, Dick MC, Rees DC. Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br J Haematol 2008; 140:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/34\">",
"      Chang Milbauer L, Wei P, Enenstein J, et al. Genetic endothelial systems biology of sickle stroke risk. Blood 2008; 111:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/35\">",
"      Adams RJ, Nichols FT, Figueroa R, et al. Transcranial Doppler correlation with cerebral angiography in sickle cell disease. Stroke 1992; 23:1073.",
"     </a>",
"    </li>",
"    <li>",
"     Adams RJ, McKie VC, McKie K, et al. Improving transcranial Doppler (TCD) predictive criteria for ischemic stroke. Proceedings of the 18th Annual Meeting of the Sickle Cell Program, Philadelphia, May 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/37\">",
"      Verlhac S, Bernaudin F, Tortrat D, et al. Detection of cerebrovascular disease in patients with sickle cell disease using transcranial Doppler sonography: correlation with MRI, MRA and conventional angiography. Pediatr Radiol 1995; 25 Suppl 1:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/38\">",
"      Abboud MR, Cure J, Granger S, et al. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood 2004; 103:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/39\">",
"      Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992; 326:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/40\">",
"      Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008; 112:4314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/41\">",
"      Fullerton HJ, Gardner M, Adams RJ, et al. Obstacles to primary stroke prevention in children with sickle cell disease. Neurology 2006; 67:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/42\">",
"      Rees DC, Dick MC, Height SE, et al. A simple index using age, hemoglobin, and aspartate transaminase predicts increased intracerebral blood velocity as measured by transcranial Doppler scanning in children with sickle cell anemia. Pediatrics 2008; 121:e1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/43\">",
"      Raphael JL, Shetty PB, Liu H, et al. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality. Pediatr Blood Cancer 2008; 51:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/44\">",
"      McCarville MB, Goodin GS, Fortner G, et al. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. Pediatr Blood Cancer 2008; 50:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/45\">",
"      Cheung AT, Harmatz P, Wun T, et al. Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. Blood 2001; 97:3401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/46\">",
"      Gorman MJ, Nystr&ouml;m K, Carbonella J, Pearson H. Submandibular TCD approach detects post-bulb ICA stenosis in children with sickle cell anemia. Neurology 2009; 73:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/47\">",
"      Valadi N, Silva GS, Bowman LS, et al. Transcranial Doppler ultrasonography in adults with sickle cell disease. Neurology 2006; 67:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/48\">",
"      Silva GS, Vicari P, Figueiredo MS, et al. Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler findings. Stroke 2009; 40:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/49\">",
"      Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/50\">",
"      Kwiatkowski JL, Granger S, Brambilla DJ, et al. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. Br J Haematol 2006; 134:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/51\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/52\">",
"      Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004; 103:3689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/53\">",
"      Wang CJ, Kavanagh PL, Little AA, et al. Quality-of-care indicators for children with sickle cell disease. Pediatrics 2011; 128:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/54\">",
"      Hankins JS, Fortner GL, McCarville MB, et al. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol 2008; 142:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/55\">",
"      Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/56\">",
"      Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/57\">",
"      Abboud MR, Yim E, Musallam KM, et al. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood 2011; 118:894.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical alert from the National Heart, Lung, and Blood Institute www.nhlbi.nih.gov/health/prof/blood/sickle/clinical-alert-scd.htm (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/59\">",
"      Hulbert ML, Scothorn DJ, Panepinto JA, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006; 149:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/60\">",
"      Wilimas J, Goff JR, Anderson HR Jr, et al. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr 1980; 96:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/61\">",
"      Lusher JM, Haghighat H, Khalifa AS. A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol 1976; 1:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/62\">",
"      Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/63\">",
"      Aygun B, McMurray MA, Schultz WH, et al. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol 2009; 145:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/64\">",
"      Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002; 99:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/65\">",
"      Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011; 117:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/66\">",
"      Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011; 117:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/67\">",
"      Cohen AR, Martin MB, Silber JH, et al. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 1992; 79:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/68\">",
"      Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/69\">",
"      Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood 2000; 96:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/70\">",
"      Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005; 105:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/71\">",
"      Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004; 145:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/72\">",
"      Zimmerman SA, Schultz WH, Burgett S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007; 110:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/73\">",
"      Kratovil T, Bulas D, Driscoll MC, et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 2006; 47:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/74\">",
"      Lef&egrave;vre N, Dufour D, Gulbis B, et al. Use of hydroxyurea in prevention of stroke in children with sickle cell disease. Blood 2008; 111:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/75\">",
"      Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002; 140:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/76\">",
"      Rogers ZR, Buchanan GR. Expanding the role of hydroxyurea in children with sickle cell disease. J Pediatr 2004; 145:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/77\">",
"      Kwiatkowski JL, Cohen AR, Garro J, et al. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. Am J Hematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/78\">",
"      Ware RE, Helms RW, SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012; 119:3925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/79\">",
"      Strouse JJ, Hulbert ML, DeBaun MR, et al. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 2006; 118:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/80\">",
"      Oyesiku NM, Barrow DL, Eckman JR, et al. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J Neurosurg 1991; 75:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/81\">",
"      Anson JA, Koshy M, Ferguson L, Crowell RM. Subarachnoid hemorrhage in sickle-cell disease. J Neurosurg 1991; 75:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/82\">",
"      Overby MC, Rothman AS. Multiple intracranial aneurysms in sickle cell anemia. Report of two cases. J Neurosurg 1985; 62:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/83\">",
"      Pavlakis SG, Prohovnik I, Piomelli S, DeVivo DC. Neurologic complications of sickle cell disease. Adv Pediatr 1989; 36:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/84\">",
"      Powars D, Adams RJ, Nichols FT, et al. Delayed intracranial hemorrhage following cerebral infarction in sickle cell anemia. J Assoc Acad Minor Phys 1990; 1:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/85\">",
"      Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92:111.",
"     </a>",
"    </li>",
"    <li>",
"     Adams RJ, Nichols FT. Sickle cell anemia, sickle cell trait and thalassemia. In: Handbook of Clinical Neurology, Vascular Disease Part III, Vinken PJ, Bruyn GW, Klawans HL (Eds), Elsevier, Amsterdam 1989. p.503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/87\">",
"      Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 1978; 9:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/88\">",
"      Hankinson TC, Bohman LE, Heyer G, et al. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg Pediatr 2008; 1:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/89\">",
"      Resar LM, Oliva MM, Casella JF. Skull infarction and epidural hematomas in a patient with sickle cell anemia. J Pediatr Hematol Oncol 1996; 18:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/90\">",
"      Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/91\">",
"      Pavlakis SG, Bello J, Prohovnik I, et al. Brain infarction in sickle cell anemia: magnetic resonance imaging correlates. Ann Neurol 1988; 23:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/92\">",
"      Zimmerman RA, Gill F, Goldberg HI, et al. MRI of sickle cell cerebral infarction. Neuroradiology 1987; 29:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/93\">",
"      Wiznitzer M, Ruggieri PM, Masaryk TJ, et al. Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography. J Pediatr 1990; 117:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/94\">",
"      Steen RG, Langston JW, Reddick WE, et al. Quantitative MR imaging of children with sickle cell disease: striking T1 elevation in the thalamus. J Magn Reson Imaging 1996; 6:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/95\">",
"      Kogutt MS, Goldwag SS, Gupta KL, et al. Correlation of transcranial Doppler ultrasonography with MRI and MRA in the evaluation of sickle cell disease patients with prior stroke. Pediatr Radiol 1994; 24:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/96\">",
"      Steen RG, Helton KJ, Horwitz EM, et al. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 2001; 49:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/97\">",
"      Telfer PT, Evanson J, Butler P, et al. Cervical carotid artery disease in sickle cell anemia: clinical and radiological features. Blood 2011; 118:6192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/98\">",
"      Powars DR, Conti PS, Wong WY, et al. Cerebral vasculopathy in sickle cell anemia: diagnostic contribution of positron emission tomography. Blood 1999; 93:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/99\">",
"      White DA, DeBaun M. Cognitive and behavioral function in children with sickle cell disease: a review and discussion of methodological issues. J Pediatr Hematol Oncol 1998; 20:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/100\">",
"      Swift AV, Cohen MJ, Hynd GW, et al. Neuropsychologic impairment in children with sickle cell anemia. Pediatrics 1989; 84:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/101\">",
"      Fowler MG, Whitt JK, Lallinger RR, et al. Neuropsychologic and academic functioning of children with sickle cell anemia. J Dev Behav Pediatr 1988; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/102\">",
"      Wasserman AL, Wilimas JA, Fairclough DL, et al. Subtle neuropsychological deficits in children with sickle cell disease. Am J Pediatr Hematol Oncol 1991; 13:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/103\">",
"      Brown RT, Armstrong FD, Eckman JR. Neurocognitive aspects of pediatric sickle cell disease. J Learn Disabil 1993; 26:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/104\">",
"      Armstrong FD, Thompson RJ Jr, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 1996; 97:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/105\">",
"      Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999; 103:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/106\">",
"      Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 2002; 99:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/107\">",
"      Casella JF, King AA, Barton B, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol 2010; 27:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/108\">",
"      DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012; 119:3684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/109\">",
"      DeBaun MR, Armstrong FD, McKinstry RC, et al. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood 2012; 119:4587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/110\">",
"      Liu JE, Gzesh DJ, Ballas SK. The spectrum of epilepsy in sickle cell anemia. J Neurol Sci 1994; 123:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/111\">",
"      Prengler M, Pavlakis SG, Boyd S, et al. Sickle cell disease: ischemia and seizures. Ann Neurol 2005; 58:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/112\">",
"      Craft S, Schatz J, Glauser TA, et al. Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr 1993; 123:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/113\">",
"      Craft S, Schatz J, Glauser T, et al. The effects of bifrontal stroke during childhood on visual attention: Evidence from children with sickle cell disease. Dev Neuropsychol 1994; 10:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/114\">",
"      White DA, Salorio CF, Schatz J, et al. Deficits in working memory related to anterior lesions in children with sickle cell disease. Neuropsychol Soc 1997; 3:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/115\">",
"      Cohen MJ, Branch WB, McKie VC, Adams RJ. Neuropsychological impairment in children with sickle cell anemia and cerebrovascular accidents. Clin Pediatr (Phila) 1994; 33:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/116\">",
"      Strouse JJ, Cox CS, Melhem ER, et al. Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA). Blood 2006; 108:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/117\">",
"      Bennett DS. Depression among children with chronic medical problems: a meta-analysis. J Pediatr Psychol 1994; 19:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/11/31930/abstract/118\">",
"      Midence K, Fuggle P, Davies SC. Psychosocial aspects of sickle cell disease (SCD) in childhood and adolescence: a review. Br J Clin Psychol 1993; 32 ( Pt 3):271.",
"     </a>",
"    </li>",
"    <li>",
"     Silent Cerebral Infarct Multi-Center Trial. National Clinical Trials Database NCT00072761. Available at: file://clinicaltrials.gov/ct2/show/NCT00072761 (Accessed on March 08, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5926 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31930=[""].join("\n");
var outline_f31_11_31930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H192012851\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CEREBRAL INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725945\">",
"      Definition and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2725926\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predicting risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624747\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2726514\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention of a first stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Stopping transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prevention of recurrent stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Chronic transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13944399\">",
"      Program costs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13160961\">",
"      SWiTCH trial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTRACRANIAL HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Moyamoya syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RADIOGRAPHIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COGNITIVE AND BEHAVIORAL DYSFUNCTION AND SILENT INFARCTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192012851\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/5926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/5926|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/38/34408\" title=\"figure 1\">",
"      Cerebrovasc dis sickle cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/31/41469\" title=\"figure 2\">",
"      CVA in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/40/4750\" title=\"figure 3\">",
"      Prevent first CVA sickle cell",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/36/7751?source=related_link\">",
"      Moyamoya disease: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_11_31931="Repeat bx HGPIN number cores";
var content_f31_11_31931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of repeat prostate biopsy in men with high grade PIN, according to the number of cores sampled",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cores, initial biopsy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cores, rebiopsy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of cancers/total number of men",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of cancer, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Six or seven",
"       </td>",
"       <td>",
"        Six or seven",
"       </td>",
"       <td>",
"        49/295",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Six or seven",
"       </td>",
"       <td>",
"        Eight or more",
"       </td>",
"       <td>",
"        47/173",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Eight or more",
"       </td>",
"       <td>",
"        Eight or more",
"       </td>",
"       <td>",
"        37/253",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Eight or more",
"       </td>",
"       <td>",
"        Six or seven",
"       </td>",
"       <td>",
"        6/70",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        Overall",
"       </td>",
"       <td>",
"        139/791",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PIN: prostatic intraepithelial neoplasia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Herawi, M, et al. J Urol 2006; 175:121.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31931=[""].join("\n");
var outline_f31_11_31931=null;
var title_f31_11_31932="OSA symptoms questionnaire";
var content_f31_11_31932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Questionnaire for exploring obstructive sleep apnea (OSA) symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Questions",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Circle one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People tell me that I snore",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I wake up at night with a feeling of shortness of breath or choking",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People tell me that I gasp, choke, or snort while I am sleeping",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        People tell me that I stop breathing while I am sleeping",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I awake feeling almost as or more tired than when I went to bed",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I often awake with a headache",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I often have difficulty breathing through my nose",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I fight sleepiness during the day",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I fall asleep when I relax before or after dinner",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Friends, colleagues, or family comment on my sleepiness",
"       </td>",
"       <td>",
"        Y",
"       </td>",
"       <td>",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1_single\">",
"        High risk",
"       </td>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Low risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         - Male",
"        </p>",
"        <p>",
"         - Body mass index greater than 25 kg/m",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"        - Neck circumference:",
"        <ul>",
"         <li>",
"          Greater than 17 inches in men",
"         </li>",
"         <li>",
"          Greater than 16 inches in women",
"         </li>",
"        </ul>",
"        <p>",
"         - Habitual snoring/gasping noted by bed partner",
"        </p>",
"        <p>",
"         - Hypertension",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         - No snoring",
"        </p>",
"        <p>",
"         - Premenopausal",
"        </p>",
"        <p>",
"         - Thin",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Associated Professional Sleep Societies, LLC, 2010. Meoli AL, Rosen CL, Kristo D, et al. Upper Airway Management of the adult patient with obstructive sleep apnea in the perioperative period-avoiding complications. Sleep 2003; 26:1060. Copyright &copy; 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31932=[""].join("\n");
var outline_f31_11_31932=null;
var title_f31_11_31933="Proposed IASLC ATS ERS classification small biopsies cytology";
var content_f31_11_31933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed IASLC ATS ERS classification for small biopsies and cytology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        2004 WHO Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Small biopsy/cytology: IASLC/ATS/ERS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Mixed subtype",
"        </p>",
"        <p>",
"         Acinar",
"        </p>",
"        <p>",
"         Papillary",
"        </p>",
"        <p>",
"         Solid",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic adenocarcinoma patterns clearly present:",
"         </em>",
"        </p>",
"        <p>",
"         Adenocarcinoma, describe identifiable patterns present (including micropapillary pattern not included in 2004 WHO classification)",
"        </p>",
"        <p>",
"         Comment: If pure lepidic growth - mention an invasive component cannot be excluded in this small specimen.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchioloalveolar carcinoma (nonmucinous)",
"       </td>",
"       <td>",
"        Adenocarcinoma with lepidic pattern (if pure, add note: an invasive component cannot be excluded)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchioloalveolar carcinoma (mucinous)",
"       </td>",
"       <td>",
"        Mucinous adenocarcinoma (describe patterns present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal",
"       </td>",
"       <td>",
"        Adenocarcinoma with fetal pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucinous (colloid)",
"       </td>",
"       <td>",
"        Adenocarcinoma with colloid pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Signet ring",
"       </td>",
"       <td>",
"        Adenocarcinoma with (describe patterns present) and signet ring features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clear cell",
"       </td>",
"       <td>",
"        Adenocarcinoma with (describe patterns present) and clear cell features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No 2004 WHO counterpart - most will be solid adenocarcinomas",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic adenocarcinoma patterns not present (supported by special stains):",
"         </em>",
"        </p>",
"        <p>",
"         Non-small cell carcinoma, favor adenocarcinoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Papillary",
"        </p>",
"        <p>",
"         Clear cell",
"        </p>",
"        <p>",
"         Small cell",
"        </p>",
"        <p>",
"         Basaloid",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic squamous cell patterns clearly present:",
"         </em>",
"        </p>",
"        <p>",
"         Squamous cell carcinoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No 2004 WHO counterpart",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic squamous cell patterns not present (supported by stains):",
"         </em>",
"        </p>",
"        <p>",
"         Non-small cell carcinoma, favor squamous cell carcinoma",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Small cell carcinoma",
"        </strong>",
"       </td>",
"       <td>",
"        Small cell carcinoma",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Large cell carcinoma",
"        </strong>",
"       </td>",
"       <td>",
"        Non-small cell carcinoma, not otherwise specified (NOS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Large cell neuroendocrine carcinoma (LCNEC)",
"       </td>",
"       <td>",
"        Non-small cell carcinoma with neuroendocrine (NE) morphology (positive NE markers), possible LCNEC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Large cell carcinoma with NE morphology (LCNEM)",
"       </td>",
"       <td>",
"        <p>",
"         Non-small cell carcinoma with NE morphology (negative NE markers)",
"        </p>",
"        <p>",
"         Comment: This is a non-small cell carcinoma where LCNEC is suspected, but stains failed to demonstrate NE differentiation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Adenosquamous carcinoma",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic squamous cell and adenocarcinoma patterns present:",
"         </em>",
"        </p>",
"        <p>",
"         Non-small cell carcinoma, with squamous cell and adenocarcinoma patterns",
"        </p>",
"        <p>",
"         Comment: This could represent adenosquamous carcinoma.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No counterpart in 2004 WHO classification",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Morphologic squamous cell or adenocarcinoma patterns not present but immunostains favor separate glandular and adenocarcinoma components",
"         </em>",
"        </p>",
"        <p>",
"         Non-small cell carcinoma, NOS, (specify the results of the immunohistochemical stains and the interpretation)",
"        </p>",
"        <p>",
"         Comment: This could represent adenosquamous carcinoma.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Sarcomatoid carcinoma",
"        </strong>",
"       </td>",
"       <td>",
"        Poorly differentiated NSCLC with spindle and/or giant cell carcinoma (mention if adenocarcinoma or squamous carcinoma are present)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IASLC: International Association for the Study of Lung Cancer; ATS: American Thoracic Society; ERS: European Respiratory Society; WHO: World Health Organization; NSCLC: non-small cell lung cancer; IHC: immunohistochemistry; TTF: thyroid transcription factor.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31933=[""].join("\n");
var outline_f31_11_31933=null;
var title_f31_11_31934="Management of functional dyspepsia";
var content_f31_11_31934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Figure 4. Management of functional dyspepsia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <em>",
"      H. pylori",
"     </em>",
"     :",
"     <em>",
"      Helicobacter pylori",
"     </em>",
"     ; PPI: proton pump inhibitor;",
"     <em>",
"      &nbsp;",
"     </em>",
"     IBS: irritable bowel syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Talley NJ. Gastroenterology 2005; 129:1753.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31934=[""].join("\n");
var outline_f31_11_31934=null;
var title_f31_11_31935="Bronchogenic carcinoma CT";
var content_f31_11_31935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of a bronchogenic carcinoma shows a mass in lingula, measuring 5.5 cm in diameter (large arrow), with dystrophic calcification and hilar lymph node enlargement (small arrow). A small left pleural effusion proved to be benign, and therefore did not affect staging of the tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_11_31935=[""].join("\n");
var outline_f31_11_31935=null;
